Immune activation and immune-associated neurotoxicity in Long-COVID: A systematic review and meta-analysis of 82 studies comprising 58 cytokines/chemokines/growth factors.

(1-4) Abbas F. Almulla, (3) Yanin Thipakorn, (1,2) Bo Zhou, (5-6) Aristo Vojdani, (1,2,3,7-12) Michael Maes\*

SHORT TITLE: Immune response system in Long COVID disease

- Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital,
   School of Medicine, University of Electronic Science and Technology of China, Chengdu
   610072, China
- 2. Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, 610072, China
- 3. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- 4. Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq.
- 5. Immunosciences Lab, Inc., Los Angeles, CA 90035, USA.
- 6. Cyrex Laboratories, LLC, Phoenix, AZ 85034, USA.
- 7. Cognitive Impairment and Dementia Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

- 8. Cognitive Fitness and Biopsychological Technology Research Unit, Faculty of Medicine. Chulalongkorn University, Bangkok, 10330, Thailand, Bangkok, 10330, Thailand.
- 9. Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria.
- 10. Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria.
- 11. Strategic Research and Innovation Program for the Development of MU PLOVDIV-(SRIPD-MUP), European Union NextGenerationEU.
- 12. Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.

### \* Corresponding author:

Prof. Dr. Michael Maes, M.D., Ph.D.

Sichuan Provincial Center for Mental Health

Sichuan Provincial People's Hospital,

School of Medicine,

University of Electronic Science and Technology of China

Chengdu 610072

China

e-mail addresses:

dr.michaelmaes@hotmail.com

#### https://scholar.google.co.th/citations?user=1wzMZ7UAAAAJ&hl=th&oi=ao

Highly cited author: 2003-2023 (ISI, Clarivate)

ScholarGPS: Worldwide #1 in molecular neuroscience; #1/4 in pathophysiology Expert worldwide medical expertise ranking, Expertscape (December 2022), worldwide: #1 in CFS, #1 in oxidative stress, #1 in encephalomyelitis, #1 in nitrosative stress, #1 in nitrosation, #1 in tryptophan, #1 in aromatic amino acids, #1 in stress (physiological), #1 in neuroimmune; #2 in bacterial translocation; #3 in inflammation, #4-5: in depression, fatigue and psychiatry.

#### Abstract

**Background:** Multiple studies have shown that Long COVID (LC) disease is associated with heightened immune activation, as evidenced by elevated levels of inflammatory mediators. However, there is no comprehensive meta-analysis focusing on activation of the immune inflammatory response system (IRS) and the compensatory immunoregulatory system (CIRS) along with other immune phenotypes in LC patients.

**Objectives:** This meta-analysis is designed to explore the IRS and CIRS profiles in LC patients, the individual cytokines, chemokines, growth factors, along with C-reactive protein (CRP) and immune-associated neurotoxicity.

**Methods:** To gather relevant studies for our research, we conducted a thorough search using databases such as PubMed, Google Scholar, and SciFinder, covering all available literature up to December 20th, 2023.

**Results:** The current meta-analysis encompassed 82 studies that examined multiple immune profiles, C-reactive protein, and 58 cytokines/chemokines/growth factors in 3836 LC patients versus 4537 normal controls (NC). LC patients showed significant increases in IRS/CIRS ratio (standardized mean difference (SMD:0.156, confidence interval (CI): 0.051;0.261), IRS (SMD: 0.345, CI: 0.222;0.468), M1 macrophage (SMD: 0.421, CI: 0.290;0.551), T helper (Th)1 (SMD: 0.353, CI: 0.189;0.517), Th17 (SMD: 0.492, CI: 0.332;0.651) and immune-associated neurotoxicity (SMD: 0.327 CI: 0.205;0.448). In addition, CRP and 19 different cytokines displayed significantly elevated levels in LC patients compared to NC.

**Conclusion:** LC disease is characterized by IRS activation and increased immune-associated neurotoxicity.

Keywords: Long COVID disease, IRS, neurotoxicity, inflammation, immune activation,

cell-mediated immunity

Current research continues to reveal an increasing prevalence of various symptoms among coronavirus survivors (O'Mahoney 2023). These symptoms extend beyond chronic fatigue, affective manifestations, cognitive dysfunction, and insomnia (Badenoch, Rengasamy et al. 2022, Premraj, Kannapadi et al. 2022). This emerging condition, often referred to as 'long COVID' (LC), poses a complex challenge for healthcare systems worldwide (Prashar 2023). The persistent nature of these symptoms significantly influences survivors' quality of life and raises important questions about the long-term effects of COVID-19 (Maes, Al-Rubaye et al. 2022). Currently, research efforts are focused to delineate the mechanisms underlying these long-lasting manifestations and to develop effective treatments for LC.

Overall, it appears that the activation of immune-inflammatory pathways is one of the primary underlying factors in LC disease. Indeed, accumulating evidence suggests that LC is accompanied by a chronic immune-inflammatory response, as indicated by elevated levels of interferon (IFN)- $\gamma$ , IFN- $\beta$ , IFN- $\lambda$ 1, CXCL10, and CXCL9 (Peluso, Lu et al. 2021, Phetsouphanh, Darley et al. 2022). Espín et al.'s scoping review revealed that cytokine groups comprising IFN- $\beta$ , pentraxin 3 (PTX3); IFN- $\beta$ , PTX3, IFN- $\gamma$ ; IFN- $\beta$ , PTX3, IFN- $\lambda$ 2/3, IL-6; and a panel of 29 cytokines demonstrated relatively high accuracy in differentiating LC patients from asymptomatic controls (Espín, Yang et al. 2023).

Immune cell phenotyping has revealed an increased frequency of CD8+ T-cell, Immunoglobulin and Mucin-domain containing-3 (TIM-3)+ and CD8+, Programmed Cell Death Protein 1 (PD-1)+ TIM-3+ T cells, suggesting a chronic activation of CD8+ T cells in LC patients (Phetsouphanh, Darley et al. 2022). In LC patients, there was a

notable increase in the frequencies of CD14+CD16+ inflammatory monocytes and plasmacytoid dendritic cells marked, suggesting sustained T cell activation, likely due to persistent inflammation or antigen presentation (Phetsouphanh, Darley et al. 2022). LC patients also exhibited elevated levels of highly cytotoxic cell populations, memory natural killer (NK) cells, and persistent antigen-specific responses in CD4+ and T follicular helper cells, indicating a robust antiviral immune response (Galán, Vigón et al. 2022).

A recent meta-analysis has revealed that patients with LC have markedly higher levels of inflammatory and vascular mediators, including C-reactive protein (CRP), D-dimer, lactate dehydrogenase (LDH), and leukocytes (Yong, Halim et al. 2023). In addition, there was an observed elevation in lymphocytes and IL-6 in these patients (Yong, Halim et al. 2023). Yin et al. (2023) also reported a significant increase in IL-6 levels in LC patients compared to healthy controls (Yin, Agbana et al. 2023).

Importantly, numerous prior studies have confirmed that the phenome of LC comprises interrelated increases in chronic fatigue syndrome (CFS), depression, and anxiety symptoms, which were delineated as core symptoms of LC disease (Al-Hadrawi, Al-Rubaye et al. 2022, Al-Hakeim, Al-Rubaye et al. 2022, Al-Hakeim, Al-Rubaye et al. 2023, Al-Hakeim, Khairi Abed et al. 2023, Almulla, Al-Hakeim et al. 2023). Moreover, this LC symptom complex was strongly predicted by the severity of acute COVID-19 infection, inflammatory mediators (CRP and the NLRP-3 inflammasome), and oxidative stress biomarkers (Al-Hadrawi, Al-Rubaye et al. 2022, Al-Hakeim, Al-Rubaye et al. 2022, Al-Hakeim, Al-Rubaye et al. 2022, Al-Hakeim, Al-Rubaye et al. 2023). This is highly relevant because CFS, depression and anxiety are characterized by aberrations in the immune-inflammatory

response system (IRS), the compensatory immunoregulatory system (CIRS), and the IRS/CIRS ratio (Maes 2009, Maes, Mihaylova et al. 2012, Maes, Twisk et al. 2012, Maes and Carvalho 2018). Furthermore, CFS and affective syndromes are associated with activation of different IRS profiles, including the classical M1 macrophage, alternative M2 macrophage, T helper (Th)-1, Th-2, and Th-17 profiles, as well as an immuneassociated profiles that may cause increased neurotoxicity (Maes 2009, Maes, Mihaylova et al. 2012, Maes, Twisk et al. 2012, Maes and Carvalho 2018). Electronic Supplementary File (ESF)-1 Table 1 lists the cytokines and chemokines that were used to compute the above immune profiles and ESF-1, table 2 lists how the immune profiles were composed. The cytokines and chemokines belonging to the neurotoxicity profile all show a potential to damage the function or structure of neuronal cells or affect neuroplasticity or neurogenesis (Maes and Carvalho 2018, Maes, Rachayon et al. 2022, Almulla, Abbas Abo Algon et al. 2023, Almulla, Abdul Jaleel et al. 2023, Sreenivas, Maes et al. 2024). Consequently, increased immune-associated neurotoxicity could explain pathophysiology of the neuro-psychiatric symptoms of LC disease.

However, the two meta-analyses that examined immune functions in LC did not provide a comprehensive examination of the immune profiles, including the neurotoxicity profile (Yin, Agbana et al. 2023, Yong, Halim et al. 2023). Therefore, a more extensive examination of cytokines/chemokines/growth factor profiles in LC would be instrumental in elucidating the mechanisms of this illness. Hence, the objective of the present meta-analysis is to delineate the precise aberrations in IRS, CIRS, M1, M2 macrophages, T helper (Th)1, Th2, Th17, and neurotoxicity profiles in patients with LC. Moreover, we will also examine CRP and solitary levels of 58 different cytokines/chemokines/growth

factors in LC disease. ESF-1, Table 1 lists all cytokines, chemokines and growth factors that were examined in the present study.

### Materials and method

In conducting this study, we rigorously applied several methodological frameworks, including the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 (Page, McKenzie et al. 2021), the Cochrane Handbook for Systematic Reviews and Interventions (Cumpston, Li et al. 2019), and guidelines for Meta-Analyses of Observational Studies in Epidemiology. This analysis involved patients with LC disease and normal controls, focusing on peripheral cytokines, chemokines and growth factors, and acute phase protein, namely CRP. We then calculated composite indices reflecting different immune profiles based on individual cytokines and chemokines, including IRS, CIRS, neurotoxicity, M1 and M2 macrophages, T helper 1,2 and 17, IRS/CIRS, M1/M2 and Th1 / Th2 ratios (see ESF-1, table 2).

#### Search strategy.

In our quest to accumulate exhaustive data on immune profiles in LC, we sourced electronic databases such as PubMed/MEDLINE, Google Scholar, and SciFinder. This search, spanning from August until December 15th, 2023, was guided by specific keywords and Mesh terms listed in Table 3 of the ESF-1. To ensure comprehensive coverage, we also examined reference lists from relevant studies and earlier meta-analyses, thereby leaving no significant study unconsidered.

#### Eligibility criteria

This meta-analysis primarily focused on articles from peer-reviewed journals in English. However, it also considered grey literature and articles in Thai, French, Spanish, Turkish, German, Italian, and Arabic. The studies selected were observational, either case-control or cohort, involving controls and examining cytokines, chemokines and growth factors. The included LC patients were diagnosed based on the World Health Organization (WHO) criteria (World Health Organization 2021). Studies with baseline assessments of immune biomarkers in follow-up were also included. Studies that used unusual media (e.g., hair, saliva, whole blood, platelet-rich plasma), genetics, translational research, or did not provide a control group were not included. Studies not providing mean and standard deviation (SD) or standard error (SE) of biomarkers were initially excluded, but the authors were contacted for this information. In the absence of a response, we computed ) orean (SD) from available data using the approach of (Wan, Wang et al. 2014) and an online Mean Variance Estimation tool (hkbu.edu.hk), or estimated the mean (SD) from graphical data using Web Plot Digitizer (https://automeris.io/WebPlotDigitizer/).

# **Primary and secondary outcomes**

This meta-analysis's essential findings, presented in **Table 1**, include data on the composite scores of IRS/CIRS ratio, IRS, CIRS, M1/M1 and Th1/Th2 ratios, M1, M2, Th1, Th2, Th17, and immune-related neurotoxicity profiles. Upon determining the significance of these composite measures, we further investigated their individual indicators as secondary outcomes. These encompass solitary levels of CRP and 58 cytokines/chemokines/growth factors listed in ESF-1, Table 1.

The initial assessment of studies for inclusion in this meta-analysis was conducted by two researchers, AA and YT. They screened study titles and abstracts against set inclusion criteria. After this initial screening, we acquired and reviewed the full texts of studies that appeared to meet our criteria while excluding those that failed to meet our exclusion standards. AA and YT then meticulously catalogued relevant data into a custom-designed EXCEL file. This file captured details such as author names, dates of studies, biomarker names, mean and SD of biomarkers, participant numbers in patient and control groups, and sample sizes of the studies. Additionally, the file included information about the study design, sample types (e.g., serum, plasma, CSF, brain tissues, blood cells), post COVID period, number of patients admitted to the intensive care unit (ICU) during acute stage of illness, mean (SD) of participants' ages, gender, post-COVID period, admission to the intensive care unit (ICU) during the acute stage of illness, and geographic location of the study. Any discrepancies in data entry or interpretation were resolved by consulting with the senior author, MM.

For assessing the methodological quality of the studies included in this research, we utilized the Immunological Confounder Scale (ICS), as proposed by (Andres-Rodriguez, Borras et al. 2020) and later modified by the last author (MM) specifically for studies concerning immune activation in LC. This scale includes two distinct assessment tools: the Quality Scale and the Redpoints Scale, both detailed in Table 4 of the ESF-1. These scales have been previously employed in meta-analyses focusing on lipid peroxidation and tryptophan catabolite data in those with affective disorders (Almulla,

Thipakorn et al. 2022, Almulla, Thipakorn et al. 2023). The Quality Scale, with a scoring range from 0 (indicating lower quality) to 10 (representing higher quality), examines aspects such as the sample size, the control over confounding variables, and the sampling duration. The Redpoints Scale, in contrast, is tailored to identify potential biases in immune activation in LC studies by assessing how well critical confounding factors are controlled. A score of 0 on this scale signifies the highest level of control, whereas a score of 26 reflects a complete lack of control over confounding variables.

# Data analysis

In this meta-analysis, we utilized CMA V4 software and adhered to PRISMA guidelines, as detailed in Table 5 of the ESF-1. Our analysis required at least two studies per identified biomarker. For calculating IRS, we assumed dependence and incorporated various relevant inflammatory biomarkers into the CMA, including IL-1α, IL-1β, IL-6, TNF-α, IL-12p70, IL-15, IL-16, IL-17, IL-18, CCL2, CCL3, CCL4, CCL5, CCL7, CCL11, CXCL1, CXCL8, CXCL9, CXCL10, IL-2, IFN-α, IFN-γ, TNF-β, GM-CSF, and G-CSF. The CIRS calculation included IL-4, IL-10, sIL-1RA, and sIL-2R. In the case of neurotoxicity, we included biomarkers such as IL-1β, IL-6, TNF-α, IL-2, IFN-γ, IL-12p70, IL-16, IL-17, CCL2, CCL3, CCL5, CCL11, CXCL1, CXCL8, CXCL10, GM-CSF, and M-CSF. The classical M1 macrophage profile was computed with the inclusion of IL-1β, IL-6, TNF-α, IL-12p70, IL-15, CCL2, CCL5, CXCL1, CXCL8, CXCL9, CXCL10. The alternative M2 macrophage profile included IL-10, IL-4, IL-13, VEGF, PDGF, and sIL-1RA. Additionally, the current meta-analysis computed the a) Th1 profile by including IL-2, sIL-2R, IFN-α, IFN-γ, IL-12p70, IL-16, TNF-α, and TNF-β, b) Th2 by including IL-2, sIL-2R, IFN-α, IFN-γ, IL-12p70, IL-16, TNF-α, and TNF-β, b) Th2 by

including IL-4, IL-5, IL-9, IL-13, IL-10, and IL-6, and c) Th17 by including IL-6 and IL-17. Moreover, in the current meta-analysis, we computed the IRS/CIRS ratio by selecting a positive effect size for all IRS data and a negative effect size for CIRS biomarkers in comparing patients with normal controls while assuming dependence. Likewise, M1/M2 and Th1/Th2 ratios were computed by selecting positive effect sizes for M1 and Th1 and negative effect sizes for M2 and Th2.

In our study, we applied a random-effects model using constrained maximum likelihood for aggregating effect sizes. We considered a p-value less than 0.05 (two-tailed) as statistically significant and reported effect sizes as standardized mean differences (SMD) with 95% confidence intervals (95% CI). For categorizing effect sizes, we used SMD values of 0.80, 0.5, and 0.20 to denote large, moderate, and small effects, respectively, following Cohen's guidelines (Cohen 2013). Heterogeneity was assessed through tau-squared statistics, Q, and I<sup>2</sup> values, a method consistent with previous meta-analyses (Almulla, Supasitthumrong et al. 2022, Almulla, Thipakorn et al. 2022, Almulla, Vasupanrajit et al. 2022, Vasupanrajit, Jirakran et al. 2022, Almulla, Thipakorn et al. 2023). Meta-regression was employed to identify factors contributing to heterogeneity. Subgroup analysis, considering each determinant as a separate unit, was used to explore biomarkers variations between periods following acute illness recovery and across different mediums like serum, plasma, blood cells, and brain tissues.

Sensitivity analyses were conducted using the leave-one-out approach to assess the robustness of the effect sizes. To detect publication bias, methods including the fail-safe N technique, the continuity-corrected Kendall tau, and Egger's regression intercept were employed, with the latter two utilizing one-tailed p-values. In instances where

Egger's test suggested asymmetry, the trim-and-fill method was applied to estimate and incorporate missing studies, subsequently recalculating the adjusted effect sizes. Additionally, funnel plots, which plot study precision against standardized mean difference (SMD), were used. These plots not only show observed studies but also the

imputed missing studies, aiding in the identification of small study effects.

# Results

# Search Outcomes

In our research, we employed specific keywords and mesh terms detailed in ESF-1, Table 3 to search through literature repositories such as PubMed, Google Scholar, and SciFinder. Our initial search yielded 3792 studies, as depicted in the PRISMA flow diagram (Figure 1), which delineates the study selection and exclusion process. Following a thorough screening to eliminate irrelevant and duplicate studies, we narrowed our focus to 221 articles. Out of these, only 87 met the strict criteria for inclusion in our systematic review. The exclusion of 130 articles was due to their noncompliance with our predefined standards. Furthermore, an additional 5 articles were excluded because of the lack of clear, extractable data. Consequently, a total of 82 studies were ultimately selected for the meta-analysis, adhering to our established inclusion and exclusion guidelines (Townsend, Dyer et al. 2020, Ahearn-Ford, Lunjani et al. 2021, Aparisi, Ybarra-Falcón et al. 2021, Colarusso, Maglio et al. 2021, Gameil, Marzouk et al. 2021, Loretelli, Abdelsalam et al. 2021, Montefusco, Ben Nasr et al. 2021, Ong, Fong et al. 2021, Patterson, Guevara-Coto et al. 2021, Peluso, Lu et al. 2021, Soni, Soni et al. 2021, Sun, Tang et al. 2021, Taha, Samaan et al. 2021, Utrero-Rico, González-Cuadrado et al. 2021, Wallis, Heiden et al. 2021, Wu, Deng et al. 2021, Acosta-Ampudia, Monsalve et al. 2022, Alfadda, Rafiullah et al. 2022, Aparisi, Ybarra-Falcón et al. 2022, Arslan, Aksakal et al. 2022, Cervia, Zurbuchen et al. 2022, Corrêa, Deus et al. 2022, Díaz-Salazar, Navas et al. 2022, Dugani, Mehta et al. 2022, Durstenfeld, Peluso et al. 2022, Elizabeth, Thomas et al. 2022, Fan, Wong et al. 2022, Fernández-de-Las-Peñas, Ryan-Murua et al. 2022, Ferrando, Dornbush et al. 2022, Flaskamp, Roubal et al. 2022, Fogarty, Ward et al. 2022, García-Abellán, Fernández et al. 2022, Johannes, Andrea et al. 2022, Kruger, Vlok et al. 2022, Littlefield, Watson et al. 2022, Magdy, Eid et al. 2022, Martone, Tosato et al. 2022, Meisinger, Goßlau et al. 2022, Meltendorf, Vogel et al. 2022, Nádasdi, Sinkovits et al. 2022, Patel, Knauer et al. 2022, Patra and Ray 2022, Peluso, Sans et al. 2022, Petrella, Nenna et al. 2022, Phetsouphanh, Darley et al. 2022, Queiroz, Neves et al. 2022, Saxena, Saxena et al. 2022, Schultheiß, Willscher et al. 2022, Sibila, Perea et al. 2022, Simone, Caitlin et al. 2022, Stavileci, Özdemir et al. 2022, Taeschler, Adamo et al. 2022, Wechsler, Butuci et al. 2022, Wiech, Chroscicki et al. 2022, Zhao, Schank et al. 2022, Al-Hakeim, Abed et al. 2023, Al-Hakeim, Al-Rubaye et al. 2023, Al-Hakeim, Al-Rubaye et al. 2023, Al-Hakeim, Al-Rubaye et al. 2023, Al-Hakeim, Khairi Abed et al. 2023, Allan-Blitz, Goodrich et al. 2023, Berentschot, Drexhage et al. 2023, Berezhnoy, Bissinger et al. 2023, Elke, Alvin et al. 2023, Garcia-Gasalla, Berman-Riu et al. 2023, Gomes, Brito et al. 2023, Julia, Stephan et al. 2023, Kelly, Sonya et al. 2023, Kuchler, Günthner et al. 2023, Melhorn, Alamoudi et al. 2023, Mitrović-Ajtić, Đikić et al. 2023, Neves, Quaresma et al. 2023, Park, Dean et al. 2023, Schultheiß, Willscher et al. 2023, Scott, Pearmain et al. 2023, Siekacz, Kumor-Kisielewska et al. 2023, Sommen, Havdal et al. 2023, Stepanova, Korol et al. 2023, Teng, Song et al. 2023, Torres-Ruiz,

Lomelín-Gascón et al. 2023, Vazquez-Alejo, Tarancon-Diez et al. 2023, Xu, Zheng et al. 2023).

Our meta-analysis synthesized data from 82 studies investigating immune biomarkers (cytokines/chemokines/growth factors and CRP) using various biological samples: 50 studies used serum, 31 utilized plasma, and 1 employed PMBC media. The total participant pool included 8373 individuals, comprising 4537 normal controls and 3836 patients with LC symptoms. The age range of participants spanned from 29 to 67 years. Diverse immunoassay techniques were employed to assess the inflammatory biomarkers, flow cytometry and multiplex immunoassay were the most common techniques as detailed in ESF-1, Table 6. The United States, Spain, and Germany were the leading contributors in this research domain, with 14, 9, and 8 studies, respectively. Other significant contributions came from Italy (6 studies), Iraq (5), Brazil (4), China, India, Ireland, and the UK (3 each). Egypt, the Netherlands, Singapore, South Africa, Switzerland, and Turkey each published 2 studies. As per ESF-1, Table 6, other countries also contributed one study each to this field. This meta-analysis evaluated the median values and minimum and maximum ranges for quality and redpoint scores. The median scores for quality and redpoint were determined to be 4,5 (ranging from 2,5 to 8,5) and 11,5 (ranging from 7,5 to 15), respectively, as presented in ESF-1, Table 6.

#### **Primary outcome variables**

IRS and CIRS in Long COVID patients versus normal controls

**Table 1** and **Figure 2** show the effect size of the IRS/CIRS ratio computed from 37 studies. None of these displayed CIs entirely below zero, but 6 had CIs entirely above

zero. Additionally, 31 studies exhibited overlapping CIs with a mix of findings: 12 studies reported negative SMD values, whereas 19 had positive SMD values. **The forest plot (Figure 2)** indicates a significant increase in the IRS/CIRS ratio in LC patients compared to NC. Our bias analysis pointed to 3 studies missing on the right side of the forest plot, and adjusting the effect size to include these studies alters it to 0.156.

We included 62 studies to evaluate the IRS as displayed in **Table 1**. Of these, 2 studies had CIs completely below zero, while 18 showed CIs entirely above zero. A significant proportion, 42 studies, presented overlapping CIs with diverse outcomes: 19 studies noted negative SMD values, and 23 reported positive SMD values. **Table 2** and **Figure 3**, show that LC patients, compared to NC, demonstrated a significant increase in IRS. **Table 3** identified 7 studies missing on the right side of the forest plot. Including these missing studies increased the SMD value to 0.345.

In our research, the effect size for CIRS was derived from 36 studies, as detailed in **Table 1** and ESF-2, Figure 1. The analysis (**Table 2**) revealed no significant difference in CIRS levels between LC patients and NC. **Table 3** indicates no bias was found.

#### Classical M1 and alternative M2 macrophages

The effect size for the M1/M2 macrophage ratio was calculated using data from 41 studies, as shown in **Table 1**. No significant M1/M2 ratio difference between LC patients and NC was found, as shown in **Table 2** and ESF-2, Figure 2. **Table 3** shows significant bias with 8 studies missing to the right of the forest plot. The inclusion of these missing studies adjusted the SMD value to 0.162, revealing a significant increase in the M1/M2 ratio.

We integrated data from 68 studies to assess M1 macrophage activation, as indicated in **Table 1**. Within these studies, 2 demonstrated CIs entirely below zero, and 22 had CIs completely above zero. A significant number 44 studies showed overlapping CIs with varied outcomes: 19 with negative SMD and 25 with positive SMD values. **Table 2** and **Figure 4** reveal that LC patients have significantly activated M1 macrophages compared to NC. Additionally, bias analysis uncovered 7 studies missing on the right side of the forest plot, and incorporating these studies increased the SMD value to 0.421. We analyzed M2 macrophage activation across 40 studies. The results, depicted in **Table 2** and ESF-2, Figure 3, indicated no significant changes in M2 macrophage status. The bias results in **Table 3**, found no evidence of bias.

### Th1/Th2 ratio, Th1, Th2 and Th17

Our study involved an analysis of 45 studies to assess the Th1/Th2 ratio, as detailed in **Table 1** and ESF-2, Figure 4. Initially, the findings indicated no significant change in the Th1/Th2 ratio among LC patients versus NC. However, as shown in **Table 3**, imputation of 12 missing studies significantly changed our results, yielding a modest yet significant effect size of 0.149.

We analyzed the effect size of Th1 using data from 45 studies as displayed in **Table 1**. Among these, 4 studies had CIs entirely below zero, while 11 showed CIs entirely above zero. Additionally, 30 studies demonstrated overlapping CIs, resulting in mixed findings: 14 reported negative SMD and 16 had positive SMD values. **Table 2 and Figure 5** show significantly increased Th1 activation in LC patients compared to NC.

**Table 3** revealed that including 6 missing studies on the right side of the forest plot increased the effect size to 0.353.

The effect size of Th2 was assessed by analyzing 57 studies, as shown in **Table 1**. Of these studies, 4 displayed CIs entirely below zero, whereas 20 had CIs completely above zero. Furthermore, 33 studies exhibited overlapping CIs, leading to various outcomes: 19 studies with negative SMD and 14 with positive SMD values. **Table 2 and** ESF-2, Figure 5 indicate significant Th2 activation in LC patients compared to NC. Our bias analysis indicated no studies were missing.

Table 1 shows that data from 55 studies was incorporated to assess Th17 levels. Within these studies, 3 had CIs entirely below zero, while 22 exhibited CIs completely above zero. Additionally, 31 studies with overlapping CIs yielded diverse results: 16 reported negative SMD, and 14 presented positive SMD values. Table 2 and Figure 6 show that LC patients displayed significantly activated Th17 compared to NC. Egger's and Kendall's tests (Table 3) detected 10 missing studies on the right side of the forest plot; imputing them would increase the SMD value to 0.492.

#### *Immune-related neurotoxicity*

We assessed neurotoxicity by analyzing data from 62 studies, as detailed in **Table**1. The findings varied across these studies: 8 had CIs entirely below zero, 22 entirely above zero, and 32 had overlapping CIs, resulting in 20 studies showing negative SMD and 12 showing positive SMD values. **Table 2 and Figure 7**, show that LC patients had significantly higher neurotoxicity index than the NC group. Table 3 identified 5 missing

studies on the right side of the forest plot, and their inclusion increased the SMD value to 0.327.

### Secondary outcome variables

CRP

**Table 1** displays that the CRP levels were analyzed using data from 38 studies. Of these, 2 studies had CIs entirely below zero, and 16 displayed CIs entirely above zero. A significant number of 20 studies presented overlapping CIs, leading to mixed results: 5 studies showed negative SMD, while 15 indicated positive SMD values. **Table 2 and** ESF-2 Figure 6 demonstrate a significant increase (with moderate effect size) in CRP levels in LC patients compared to the NC group. Bias analysis in **Table 3** identified 10 missing studies on the right side of the forest plot. Including these missing studies amplified the effect size to 0.776.

IL-6

ESF-2, Table 1 indicates that IL-6 levels were evaluated across 52 studies. These studies showed a range of outcomes: 3 had CIs entirely below zero, 23 had CIs completely above zero, and 26 displayed overlapping CIs, resulting in 15 studies with negative SMD and 11 with positive SMD values. ESF-2, Table 2 and Figure 7, indicate that IL-6 levels significantly increased in LC patients compared to the NC group. ESF-2, Table 3 shows that including 7 missing studies on the right side of the forest plot raises the SMD value.

Our study's evaluation of IL-1β involved 23 studies, as shown in ESF-2, Table 1. These studies varied in their findings: 2 reported CIs entirely below zero, 8 entirely above zero, and 13 with overlapping CIs. This resulted in 6 studies showing negative SMD and 7 showing positive SMD values. ESF-2, Figure and Table 2 indicate that LC patients have significantly increased IL-1β levels compared to the NC group. ESF-2, Table 3 revealed that including 2 missing studies on the right side of the forest plot adjusts the SMD value to 0.484.

TNF-α

The assessment of TNF- $\alpha$  levels involved the analysis of 41 studies, as detailed in ESF-2, Table 1 and Figure 9. The findings across these studies were diverse: 5 studies had CIs entirely below zero, 11 had CIs completely above zero, and 25 showed overlapping CIs, leading to 13 studies with negative SMD and 12 with positive SMD values. ESF-2, Table 2 reveals that LC patients have significantly higher TNF- $\alpha$  levels than the NC group. Egger's and Kendall's tests identified 8 missing studies on the right side of the forest plot, and adjusting the SMD value to these studies increased it.

*IL-2* 

The analysis of IL-2 levels was conducted using data from 17 studies, as shown in ESF-2, Table 1. The results from these studies varied: 2 showed CIs entirely below zero, 6 entirely above zero, and 9 had overlapping CIs. This diversity led to 5 studies reporting negative SMD and 4 reporting positive SMD values. ESF-2, Table 2 and Figure 10 reveal

that IL-2 levels were significantly elevated in LC patients compared to the NC group.

One missing study on the right side of the forest plot was identified, and implementing

this study raises the SMD value.

*IL-22* 

We utilized data from four studies to assess IL-22 levels, as presented in ESF-1,

Table 1. These studies showed varied results: none had CIs entirely below zero, two had

CIs entirely above zero, and 2 had overlapping CIs. This resulted in 1 study indicating a

negative SMD and another showing a positive SMD. ESF-2, Figure 11 and Table 2 show

that LC patients exhibited significantly elevated IL-22 levels compared to the NC group.

ESF-2, Table 3 highlights that incorporating 1 missing study on the right side of the forest

plot amplifies the effect size to 0.482.

*IL-7* 

We assessed IL-7 levels using data from 12 studies, as indicated in ESF-2, Table

1. The results from these studies were diverse: 3 studies had CIs entirely below zero, 2

entirely above zero, and 7 exhibited overlapping CIs. Consequently, 3 studies reported

negative SMD, while 4 showed positive SMD values. ESF-2, Table 2 and Figure 12

indicate no significant changes in IL-7 levels. Egger's and Kendall's tests identified 3

missing studies on the right side of the forest plot, and their inclusion led to significant

results with a moderate effect size of 0.585.

*IP-10* 

The evaluation of IP-10 levels was conducted using data from 20 studies, as detailed in ESF-2, Table 1. These studies presented a range of outcomes: 1 had CIs entirely below zero, 4 had CIs completely above zero, and 15 showed overlapping CIs. As a result, 5 studies reported negative SMD, while 10 indicated positive SMD values. ESF-2, Table 2 and Figure 13 reveal significantly higher levels of IP-10 in LC patients compared to the NC group. ESF-2, Table 3 shows that including 1 missing study, identified on the right side of the forest plot, raised the SMD value.

*IL-8* 

Our research analyzed IL-8 levels by synthesizing data from 21 studies, as shown in ESF-2, Table 1. The findings varied, with 1 study having CIs entirely below zero, 8 entirely above zero, and 12 with overlapping CIs. This led to 8 studies indicating negative SMD, while 4 reported positive SMD values. ESF-2, Table 2 and Figure 14 indicate significantly elevated IL-8 levels in LC patients compared to NC. ESF-2, Table 3 shows that 2 missing studies were identified on the right side of the forest plot, which increased the SMD value after imputing them.

**VEGF** 

We assessed VEGF levels by integrating findings from 12 studies, as outlined in ESF-2, Table 1. The outcomes were diverse: none of the studies had CIs entirely below zero, 2 had CIs completely above zero, and 10 exhibited overlapping CIs. Consequently, this variability led to 4 studies showing negative SMD and 6 demonstrating positive SMD values. ESF-2, Table 2 and Figure 15 reveal that VEGF levels were significantly

increased in LC patients versus the NC group. Incorporating two missing studies,

identified on the right side of the forest plot, resulted in an increased SMD value.

*IL-13* 

Our analysis of IL-13 levels involved data from 11 studies, as detailed in ESF-2,

Table 1. These studies showed considerable variation: no study reported CIs entirely

below zero, 6 had CIs entirely above zero, and 5 presented overlapping CIs. This led to 1

study with a negative SMD and 4 with positive SMD values.ESF-2, Table 2 and Figure

16 indicate IL-13 levels significantly increased in LC patients versus NC. No bias was

detected in these results.

MIP-1α

We examined MIP-1α levels by analyzing data from 9 studies, as presented in

ESF-2, Table 1. The outcomes of these studies showed significant variation: 1 study had

CIs entirely below zero, 4 displayed CIs completely above zero, and 4 had overlapping

CIs. This resulted in a mix of findings, with 2 studies reporting negative SMD and 2

indicating positive SMD values. ESF-2, Table 2 and Figure 17 reveal that MIP-1α levels

were significantly increased in LC patients versus NC. Egger's and Kendall's tests found

1 missing on the right side of the forest plot, leading to increased effect size.

IL-1Ra

IL-1Ra levels were examined using data from 8 studies, as outlined in ESF-2,

Table 1 of our research. The findings from these studies varied, with none showing CIs

entirely below zero, 4 with CIs completely above zero, and 4 displaying overlapping CIs.

Consequently, all the included studies showed positive SMD values. ESF-2, Table 2 and

Figure 18 indicate IL-1Ra levels were significantly increased (with a large effect size) in

LC patients versus NC. These results were absent from bias.

G-CSF

We evaluated G-CSF levels using data from 6 studies, as indicated in ESF-2,

Table 1. These studies exhibited a range of outcomes: none had CIs entirely below zero, 3

had CIs completely above zero, and 3 showed overlapping CIs. Notably, all the studies

resulted in positive SMD values. ESF-2, Table 2 and Figure 19 reveal that G-CSF levels

were significantly increased in LC patients versus the NC group. ESF-2, Table 3 revealed

1 missing study on the right side of the forest plot, imputing it led to a huge SMD value

of 1.027.

VCAM-1

We analyzed VCAM-1 levels from 6 studies, as detailed in ESF-2, Table 1. The

outcomes of these studies varied: none showed CIs entirely below zero, 1 had a CI

completely above zero, and 5 had overlapping CIs. This resulted in 1 study with a

negative SMD and 4 with positive SMD values. ESF-2, Table 2 and Figure 20 indicate

that VCAM-1 levels were significantly increased in LC patients versus NC. Egger's and

Kendall's tests revealed 3 missing studies on the left side of the forest plot, and including

these studies reduced the effect size, rendering it no longer significant.

**EGF** 

EGF levels were examined by incorporating findings from 4 studies, as shown in ESF-2, Table 1. The results from these studies were diverse: none had CIs entirely below zero, 1 displayed a CI entirely above zero, and 3 exhibited overlapping CIs. This variability led to 1 study reporting a negative SMD and 2 indicating positive SMD values. ESF-2, Table 2 and Figure 21 indicate that EGF levels were significantly increased in LC patients versus NC. One missing study on the right side of the forest plot was detected, and imputing it raised the SMD value of 0.616.

MCP-4

We examined MCP-4 levels using data from 3 studies, as outlined in ESF-2, Table 1. The study outcomes showed variation: none had CIs entirely below zero, 1 had a CI completely above zero, and 2 had overlapping CIs. All studies reported positive SMD values. ESF-2, Table 2 and Figure 22 reveal that MCP-4 levels were significantly increased in LC patients versus NC. Incorporating 1 missing study, identified on the right side of the forest plot and adjusted the SMD value to 0.607.

MIP-3α

MIP-3 $\alpha$  levels were assessed using data from 3 studies, as indicated in ESF-2, Table 1. These studies uniformly showed CIs entirely above zero. ESF-2, Table 2 and Figure 23 indicate that MIP-3 $\alpha$  levels were significantly increased in LC patients versus NC. Including two missing studies on the left side of the forest plot, as shown in ESF-2, Table 3 led to an adjusted SMD value of 0.638.

CXCL1

Our study's examination of CXCL1 levels involved data from 3 studies, detailed in ESF-2, Table 1, which consistently displayed CIs entirely above zero. ESF-2, Table 2 and Figure 24 reveal that CXCL1 levels were significantly increased in LC patients versus NC. ESF-2, Table 3 indicates no bias was found.

SCF

We analyzed SCF levels by synthesizing findings from 2 studies, as outlined in ESF-2, Table 1, where both consistently showed CIs entirely above zero. ESF-2, Table 2 and Figure 25 reveal that CXCL1 levels were significantly increased in LC patients versus NC.

This meta-analysis detected no significant differences between LC patients and NC in IL-10, MCP-1, MCP-3, CXCL11, CXCL9, Eotaxin, FGF, GM-CSF, HGF, ICAM, IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IL-12, IL-15, IL-16, IL-17, IL-18, IL-1 $\alpha$ , IL-21, IL-23, IL-27, IL-2Ra, IL-3, IL-33, IL-4, IL-5, IL-9, M-CSF, MIP-1 $\beta$ , MIP-3 $\beta$ , PDGF, PIGF, PECAM, RANTES, sRAGE, TGF- $\alpha$ , TGF- $\beta$ , and TNF-  $\beta$ .

#### **Results of Meta-Regression**

Meta-regression analysis was carried out to clarify the individual components contributing to the heterogeneity in research addressing immune-inflammatory profiles and isolated cytokines/chemokines/growth factors in LC patients. Our findings revealed that latitude and increasing number of hospitalized patients during the acute phase

significantly impact most of the outcomes except Th2, TNF-α, IL-22, IL-7, IP-10, IL-8,

IL-13, MIP-1α, G-CSF, and VCAM-1 as shown in ESF-1, Table 7. Age and the more than

6 months post-COVID period also significantly influence several outcomes. Other

factors, including admission to the intensive care unit during the acute phase of illness,

BMI and less than 3 months post-infection, and serum media, also show substantial

contributions to the heterogeneity, as presented in ESF-1, Table 7.

**Discussion** 

This meta-analysis, which is currently the most extensive in its field, explores the

impact of immune responses on LC disease. It offers new insights through an analysis of

82 studies related to LC, examining different immune profiles and an immune-related

neurotoxicity index along with CRP and 58 individual levels of

cytokines/chemokines/growth factors.

LC is associated with activated IRS and normal CIRS pathways.

The first key finding of the present meta-analysis reveals that LC is characterized

by a significant increase in the IRS/CIRS ratio, although with a small effect size. The

increase in this ratio is explained by activated IRS pathways, whereas the CIRS pathways

were not altered in LC. These results indicate that activated immune-inflammatory

pathways relative to the unchanged CIRS may play a significant role in the

pathophysiology of LC disease. It is worth mentioning that this meta-analysis is the first

to show upregulated IRS pathways in LC patients. However, recent meta-analyses

displayed high levels of immune-inflammatory biomarkers in LC, including IL-6 (Yin, Agbana et al. 2023), CRP, and leukocytes (Yong, Halim et al. 2023).

In our study, the major constituents of IRS activation were IL-1α, IL-1β, IL-6, TNF-α, IL-12p70, IL-15, IL-16, IL-17, IL-18, CCL2, CCL3, CCL4, CCL5, CCL7, CCL11, CXCL1, CXCL8, CXCL9, CXCL10, IL-2, IFN-α, IFN-γ, TNF-β, GM-CSF, and G-CSF. We examined the solitary levels of these biomarkers, and the results show that only IL-1β, TNF-α, IP-10 (CXCL10), IL-6, IL-8, MIP-1α (CCL3), and CXCL1 were significantly elevated in LC patients compared to controls. In contrast, CIRS components include IL-4, IL-10, sIL-1RA, and sIL-2R, and our analysis shows that only IL-1Ra was significantly elevated in LC patients. This is important as increased sIL-RA levels indicate IRS and monocytic activation, although antagonizing IL-1 signaling (Maes and Carvalho 2018). These pathways are likely implicated in LC patients' chronic fatigue and affective symptoms. Indeed, substantial evidence suggests a link between chronic fatigue, depression, and anxiety with the activation of abnormal IRS pathways (Maes, Ringel et al. 2013, Anderson, Berk et al. 2014, Maes and Carvalho 2018).

It should be noted that the current comprehensive evidence confirms our previous findings reporting that LC patients are suffering from activated immune-inflammatory responses (Al-Hakeim, Al-Rubaye et al. 2022, Al-Hakeim, Al-Rubaye et al. 2022, Al-Hakeim, Abed et al. 2023, Al-Hakeim, Al-Rubaye et al. 2023, Al-Hakeim, Khairi Abed et al. 2023, Almulla, Al-Hakeim et al. 2023, Almulla, Maes et al. 2023, Vojdani, Almulla et al. 2023). This augmentation of immune-inflammatory responses suggests a critical pathway that may contribute to the disease's progression and the onset of neuro-

psychiatric symptomatology. Consequently, targeting these immune-inflammatory responses could offer novel therapeutic avenues.

In LC disease, the persistence of immune-inflammatory reactions without activating the counter-regulatory immune system, as indicated in our study, may precipitate autoimmune responses in patients, potentially leading to more severe outcomes. Indeed, recent evidence, including findings by (Almulla, Maes et al. 2023, Vojdani, Almulla et al. 2023), supports this, showing that LC patients exhibit autoimmune reactions, as indicated by elevated levels of immunoglobulins (IgA, IgM, IgG) against self-proteins such as Activin A, myelin basic protein, myelin oligodendrocyte glycoprotein, and synapsin. Consequently, this state of neuro-autoimmunity, driven by persistently activated immune responses, can render COVID-19 survivors susceptible to neurological or mental symptoms (Strong 2023). The presence of heightened autoimmune markers is significantly linked to more advanced stages of LC, emphasizing the necessity of early identification and precise interventions for these patients.

*Increased cell-mediated immunity in LC disease.* 

The second key finding of the present study is that LC disease is characterized by a notable rise in M1/M2 and Th1/Th2 ratios, albeit with small effect sizes that become apparent after accounting for missing studies. Furthermore, our investigation also shows a significant increase in the activation of Th1, Th2, Th17, and M1 in LC disease. Thus, the smaller alterations in the M1/M2 and Th1/Th2 ratios can be attributed to the heightened activity of these specific T lymphocytes and the macrophage M1 type. The findings imply that cell-mediated immunity may be a driving factor behind LC disease

and its neuro-psychiatric symptoms. The results of our meta-analysis contrasts with those of Kovarik et al. (2023) who reported that LC disease involves a significant decrease in M1 activity and an increase in M2 activity, as indicated by cytokine secretions in their study (Kovarik, Bileck et al. 2023).

Various recent studies (Dan, Mateus et al. 2021, Peluso, Deitchman et al. 2021, Vibholm, Nielsen et al. 2021, Opsteen, Files et al. 2023) indicate a prolonged activation of SARS-CoV-2-specific T-cells, lasting up to six months post-infection. However, it's noteworthy that many of these studies report a decreasing response of T cells over time (Dan, Mateus et al. 2021, Opsteen, Files et al. 2023). This observation points to the possible presence of persistent viral reservoirs, which might be responsible for the continued SARS-CoV-2-specific responses seen in LC patients. Indeed, we recently detected SARS-CoV-2 persistence in LC patients, triggering ongoing immune responses (Vojdani, Almulla et al. 2023). It has been hypothesized that ongoing immune activation and the consequent neuroinflammation could play a role in the neurocognitive symptoms of LC, a theory supported by the observation of heightened inflammatory markers in the cerebrospinal fluid (CSF) of patients exhibiting these symptoms (Apple, Oddi et al. 2022).

In LC patients compared to uninfected individuals, there is a significant elevation in plasma levels of cytokines and chemokines, particularly those related to macrophage response to Type 2 cytokines, including IL-5, IL-9, IL-17F, IL-18, IL-22, IL-23, IL-33, CCL2/MCP-1, and sCD163 (Schultheiß, Willscher et al. 2023). Further research highlighted significant changes in post-COVID-19 patients, especially in T-cell dynamics. Severe LC cases often show a pronounced shift toward an exhausted or

senescent phenotype in CD4+ and CD8+ T cells, with noticeable disturbances in CD4+ T regulatory cells, indicating the intricate nature of immune responses in LC disease (Wiech, Chroscicki et al. 2022, Berentschot, Drexhage et al. 2023). Additionally, Ruiz et al. (2023) found a significant increase in CD57 expression on CD8+ T cells, suggesting a shift towards a pro-inflammatory state that could contribute to the persistence of LC symptoms (Torres-Ruiz, Lomelín-Gascón et al. 2023). These findings suggest that low-grade persistent inflammatory responses in LC might be predominantly driven by cell-mediated immunity.

### CRP and the acute phase response in LC

The present study's third key finding reveals that patients with LC exhibit significantly elevated CRP levels compared to the control group with a large effect size. This observation aligns with and builds upon the findings of previous meta-analysis (Yong, Halim et al. 2023) and research (Wallis, Heiden et al. 2021, Al-Hakeim, Al-Rubaye et al. 2022, Littlefield, Watson et al. 2022, Al-Hakeim, Al-Rubaye et al. 2023, Al-Hakeim, Khairi Abed et al. 2023), which consistently report elevated CRP levels in LC patients, suggesting a pronounced acute phase response in this group. In contrast to the previous meta-analysis by (Yong, Halim et al. 2023), which synthesized effect sizes from only 10 studies, the current study encompasses 38 studies, thereby enhancing the precision in the calculation of the effect sizes. Importantly, we previously detected that peak body temperature during the acute COVID stage could significantly predict CRP in LC patients (Al-Hakeim, Al-Rubaye et al. 2022).

An acute phase response is a hallmark of LC, where inflammatory cytokines like interleukin-6 (IL-6) prompt the liver to increase CRP production (Almulla, Al-Hakeim et al. 2023). Other conditions in LC, including autoimmunity (Almulla, Maes et al. 2023), gut dysbiosis (Zhang, Zhou et al. 2023), and thrombosis (Dasari, Banga et al. 2022) may also trigger the production of CRP. CRP plays a role in compromising the integrity of the blood-brain barrier (BBB), through its action in enhancing vascular permeability, stimulating microglia, increasing oxidative stress, and enabling the infiltration of inflammatory cells and cytokines into the central nervous system, possibly resulting in neuroinflammation and neurodegeneration (Kuhlmann, Librizzi et al. 2009, Closhen, Bender et al. 2010, Hsuchou, Kastin et al. 2012). Overall, high CRP levels in LC patients are probably partly responsible for the manifestations of CFS and affective symptoms. Indeed, we recently detected that CRP is one of the best predictors for neuropsychiatric symptoms in LC disease (Al-Hakeim, Khairi Abed et al. 2023, Almulla, Maes et al. 2023, Vojdani, Almulla et al. 2023).

# *Immune-associate neurotoxicity*

Another key finding of our study is the observation of increased immune-associated neurotoxicity in LC disease, calculated by aggregating neuro-immunotoxic mediators including IL-1β, IL-6, TNF-α, IL-2, IFN-γ, IL-12p70, IL-16, IL-17, CCL2, CCL3, CCL5, CCL11, CXCL1, CXCL8, CXCL10, GM-CSF, and M-CSF. This builds on our previous discovery that LC patients exhibit heightened immune-associated neurotoxicity, as measured by a composite based on the sum of inflammatory, insulin resistance, and oxidative stress biomarkers, which associates with a reduced quality of

life in these patients (Al-Hakeim, Al-Naqeeb et al. 2023, Almulla, Ali Abbas Abo et al. 2023a). These studies have consistently found a significant association between chronic fatigue, affective symptoms (major LC symptoms), and immune-associated neurotoxicity. Further research indicates that certain products of M1 (e.g., IL-1β, IL-6, IL-15, TNF-α, CCL2, CCL5, CXCL10), Th1 (like IL-2, IFN-γ, IL-16), Th17 (such as IL-6 and IL-17), and even Th2 (for instance, IL-4), can impair neuronal functions related to mood regulation, leading to neuro-affective toxicity and potentially resulting in depression (Maes, Rachayon et al. 2022).

Those findings suggest that LC disease may be regarded as a complex exogenous neuro-psychiatric disorder with relative nosological specificity (Di Nicola and Stoyanov 2021). In that theoretical framework, exogenous neurotoxic neuro-psychiatric conditions are caused by environmental agents which realize pathogenic effects based on relatively specific pathways and the clinical manifestations associated with them.

### Heterogeneity issues.

Our meta-regression analysis reveals a significant inverse association between age and various inflammatory biomarkers, including IRS/CIRS, neurotoxicity, M1/M2, Th17, and CRP. This suggests a more pronounced inflammatory state in younger COVID-19 survivors. Such findings align with the concept of immunosenescence, which involves the gradual weakening of the immune system with aging, leading to alterations in immune responses like cytokine production variability (Ventura, Casciaro et al. 2017). Additionally, the onset of LC after more than 6 months shows a significant direct correlation with regulatory immune responses, including CIRS, M2 macrophage, and

Th2, while an early onset (less than 3 months) is associated with Th17 and IL-17.

Furthermore, IRS, neurotoxicity, M1, Th1/Th2, Th1, Th17, CRP, IL-1β, and IL-2 display

an inverse relationship with the latitude of the countries where patients reside. These

results suggest that the proinflammatory state of LC is more pronounced in patients living

closer to the equator. Other important factors influencing these biomarkers are detailed in

the ESF-1 Table 7.

Limitations

Despite the novel insights offered by this meta-analysis, it is important to

acknowledge certain limitations that may affect the interpretation of its findings. The

findings of this study would have been further enriched if we had the opportunity to

investigate the interplay between neuro-oxidative and neuroimmune-inflammatory

pathways in the context of LC. Due to the lack of medication-related information in most

of the studies we analyzed, this study did not assess the impact of medications. Therefore,

future research should include details on treatments administered during the acute phase

or in LC cases. Our study did not examine the effects of COVID-19 vaccinations on

inflammatory biomarkers due to the absence of relevant data in the studies we included.

Future research should, therefore, include information on vaccination status. Our study

could not conduct meta-analyses for CXCL12, IL-29, IL-31, MCP-2, MCP-3, TNFR2,

TNFSF9, TNFSF10, TNFSF12, TNFSF14, and sVEGFR, because only one study was

available.

Conclusion

This comprehensive and large-scale meta-analysis, the first of its scale

incorporating 82 studies, indicates that LC patients typically exhibit heightened immune-

inflammation, enhanced cell-mediated immunity, and immune-related neurotoxicity.

These findings open up potential new treatment avenues targeting these specific pathways

for LC management.

**Declaration of Competing Interests** 

The authors affirm that no conflicts of interest are associated with this manuscript.

Ethical approval and consent to participate.

Not applicable.

Consent for publication.

Not applicable.

Availability of data and materials

Upon full utilization by all authors, the last author, MM, will address legitimate

inquiries for the dataset used in this meta-analysis, which will be shared in an Excel file

format.

Funding

The study was funded by the C2F program, Chulalongkorn University, Thailand, No.

64.310/436/2565 to AFA, an FF66 grant and a Sompoch Endowment Fund (Faculty of

Medicine), MDCU (RA66/016) to MM, and Grant № BG-RRP-2.004-0007-C01

"Strategic Research and Innovation Program for the Development of MU - PLOVDIV-

(SRIPD-MUP)", Creation of a network of research higher schools, National plan for

recovery and sustainability, European Union – NextGenerationEU.

**Author's contributions** 

AA and MM were responsible for designing the present study, while YT and AA

collected the data. YT and AA independently verified the data accuracy. AA and MM

conducted the statistical analysis. All authors have actively participated in the drafting

and revising of the manuscript and have provided their approval for the submission of the

final version.

Acknowledgments

Not applicable.

# 37

## References

Acosta-Ampudia, Y., D. M. Monsalve, M. Rojas, Y. Rodríguez, E. Zapata, C. Ramírez-Santana and J. M. Anaya (2022). "Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome." <u>J Infect Dis</u> **225**(12): 2155-2162.

Ahearn-Ford, S., N. Lunjani, B. McSharry, J. MacSharry, L. Fanning, G. Murphy, C. Everard, A. Barry, A. McGreal, S. M. Al Lawati, S. Lapthorne, C. Sherlock, A. McKeogh, A. Jackson, E. Faller, M. Horgan, C. Sadlier and L. O'Mahony (2021). "Long-term disruption of cytokine signalling networks is evident in patients who required hospitalization for SARS-CoV-2 infection." Allergy **76**(9): 2910-2913.

Al-Hadrawi, D. S., H. T. Al-Rubaye, A. F. Almulla, H. K. Al-Hakeim and M. Maes (2022). "Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to Long COVID: A precision nomothetic approach." <u>Acta Neuropsychiatrica</u>: 1-12.

Al-Hakeim, H. K., A. K. Abed, A. F. Almulla, S. Rouf Moustafa and M. Maes (2023). "Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway." Asian Journal of Psychiatry 88: 103723.

Al-Hakeim, H. K., T. H. Al-Naqeeb, A. F. Almulla and M. Maes (2023). "The physioaffective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium." <u>Journal of Affective Disorders</u> **331**: 300-312.

Al-Hakeim, H. K., H. T. Al-Rubaye, D. S. Al-Hadrawi, A. F. Almulla and M. Maes (2022). "Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study." Molecular Psychiatry.

Al-Hakeim, H. K., H. T. Al-Rubaye, D. S. Al-Hadrawi, A. F. Almulla and M. Maes (2023). "Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study." <u>Mol Psychiatry</u> **28**(2): 564-578.

Al-Hakeim, H. K., H. T. Al-Rubaye, A. F. Almulla, D. S. Al-Hadrawi and M. Maes (2022). "Chronic fatigue, depression and anxiety symptoms in Long COVID are strongly

predicted by neuroimmune and neuro-oxidative pathways which are caused by the inflammation during acute infection." <u>medRxiv</u>: 2022.2006.2029.22277056.

Al-Hakeim, H. K., H. T. Al-Rubaye, A. F. Almulla, D. S. Al-Hadrawi and M. Maes (2023) "Chronic Fatigue, Depression and Anxiety Symptoms in Long COVID Are Strongly Predicted by Neuroimmune and Neuro-Oxidative Pathways Which Are Caused by the Inflammation during Acute Infection." <u>Journal of Clinical Medicine</u> **12** DOI: 10.3390/jcm12020511.

Al-Hakeim, H. K., H. T. Al-Rubaye, A. S. Jubran, A. F. Almulla, S. R. Moustafa and M. Maes (2023). "Increased insulin resistance due to Long COVID is associated with depressive symptoms and partly predicted by the inflammatory response during acute infection." Braz J Psychiatry.

Al-Hakeim, H. K., A. Khairi Abed, S. Rouf Moustafa, A. F. Almulla and M. Maes (2023). "Tryptophan catabolites, inflammation, and insulin resistance as determinants of chronic fatigue syndrome and affective symptoms in long COVID." <u>Frontiers in Molecular</u> Neuroscience **16**.

Alfadda, A. A., M. Rafiullah, M. Alkhowaiter, N. Alotaibi, M. Alzahrani, K. Binkhamis, K. Siddiqui, A. Youssef, H. Altalhi, I. Almaghlouth, M. Alarifi, S. Albanyan, M. F. Alosaimi, A. Isnani, S. S. Nawaz and K. Alayed (2022). "Clinical and biochemical characteristics of people experiencing post-coronavirus disease 2019-related symptoms: A prospective follow-up investigation." <u>Frontiers in Medicine</u> **9**.

Allan-Blitz, L. T., J. Goodrich, H. Hu, O. Akbari and J. D. Klausner (2023). "Altered Tumor Necrosis Factor Response in Neurologic Postacute SARS-CoV-2 Syndrome." <u>J</u> Interferon Cytokine Res **43**(7): 307-313.

Almulla, A. F., A. Abbas Abo Algon, C. Tunvirachaisakul, H. K. Al-Hakeim and M. Maes (2023). "T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors." <u>J Adv Res</u>.

Almulla, A. F., A. K. Abdul Jaleel, A. A. Abo Algon, C. Tunvirachaisakul, H. K. Hassoun, H. K. Al-Hakeim and M. Maes (2023). "Mood Symptoms and Chronic Fatigue Syndrome Due to Relapsing-Remitting Multiple Sclerosis Are Associated with Immune Activation and Aberrations in the Erythron." <u>Brain Sci</u> **13**(7).

Almulla, A. F., H. K. Al-Hakeim and M. Maes (2023). "Chronic fatigue and affective symptoms in acute and long COVID are attributable to immune-inflammatory pathways." <u>Psychiatry Clin Neurosci</u> **77**(2): 125-126.

Almulla, A. F., A. Ali Abbas Abo, T. Chavit, K. A.-H. Hussein and M. Michael (2023a). "T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors." <u>medRxiv</u>: 2023.2004.2016.23288643.

Almulla, A. F., M. Maes, Z. Bo, K. A.-H. Hussein and V. Aristo (2023). "Brain-targeted autoimmunity is strongly associated with Long COVID and its chronic fatigue syndrome as well as its affective symptoms." <u>medRxiv</u>: 2023.2010.2004.23296554.

Almulla, A. F., T. Supasitthumrong, C. Tunvirachaisakul, A. A. A. Algon, H. K. Al-Hakeim and M. Maes (2022). "The tryptophan catabolite or kynurenine pathway in COVID-19 and critical COVID-19: a systematic review and meta-analysis." <u>BMC Infectious Diseases</u> **22**(1): 615.

Almulla, A. F., Y. Thipakorn, A. A. Algon, C. Tunvirachaisakul, H. K. Al-Hakeim and M. Maes (2023). "Reverse cholesterol transport and lipid peroxidation biomarkers in

major depression and bipolar disorder: A systematic review and meta-analysis." <u>Brain</u>, Behavior, and Immunity **113**: 374-388.

Almulla, A. F., Y. Thipakorn, C. Tunvirachaisakul and M. Maes (2023). "The tryptophan catabolite or kynurenine pathway in autism spectrum disorder; a systematic review and meta-analysis." <u>Autism Res</u> **16**(12): 2302-2315.

Almulla, A. F., Y. Thipakorn, A. Vasupanrajit, A. A. A. Algon, C. Tunvirachaisakul, A. A. H. Aljanabi, G. Oxenkrug, H. K. Al-Hakeim and M. Maes (2022). "The tryptophan catabolite or kynurenine pathway in major depressive and bipolar disorder: A systematic review and meta-analysis." Brain, Behavior, & Immunity-Health: 100537.

Almulla, A. F., Y. Thipakorn, A. Vasupanrajit, C. Tunvirachaisakul, G. Oxenkrug, H. K. Al-Hakeim and M. Maes (2022) "The Tryptophan Catabolite or Kynurenine Pathway in a Major Depressive Episode with Melancholia, Psychotic Features and Suicidal Behaviors: A Systematic Review and Meta-Analysis." Cells 11 DOI: 10.3390/cells11193112.

Almulla, A. F., A. Vasupanrajit, C. Tunvirachaisakul, H. K. Al-Hakeim, M. Solmi, R. Verkerk and M. Maes (2022). "The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments." Molecular Psychiatry 27(9): 3679-3691.

Anderson, G., M. Berk and M. Maes (2014). "Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome."

<u>Acta Psychiatrica Scandinavica</u> **129**(2): 83-97.

Andres-Rodriguez, L., X. Borras, A. Feliu-Soler, A. Perez-Aranda, N. Angarita-Osorio, P. Moreno-Peral, J. Montero-Marin, J. Garcia-Campayo, A. F. Carvalho and M. Maes

(2020). "Peripheral immune aberrations in fibromyalgia: A systematic review, metaanalysis and meta-regression." <u>Brain, behavior, and immunity</u> **87**: 881-889.

Aparisi, Á., C. Ybarra-Falcón, M. García-Gómez, J. Tobar, C. Iglesias-Echeverría, S. Jaurrieta-Largo, R. Ladrón, A. Uribarri, P. Catalá, W. Hinojosa, M. Marcos-Mangas, L. Fernández-Prieto, R. Sedano-Gutiérrez, I. Cusacovich, D. Andaluz-Ojeda, B. de Vega-Sánchez, A. Recio-Platero, E. Sanz-Patiño, D. Calvo, C. Baladrón, M. Carrasco-Moraleja, C. Disdier-Vicente, I. J. Amat-Santos and J. A. San Román (2021). "Exercise Ventilatory Inefficiency in Post-COVID-19 Syndrome: Insights from a Prospective Evaluation." J Clin Med **10**(12).

Aparisi, Á., C. Ybarra-Falcón, C. Iglesias-Echeverría, M. García-Gómez, M. Marcos-Mangas, G. Valle-Peñacoba, M. Carrasco-Moraleja, C. Fernández-de-Las-Peñas, L. Guerrero Á and D. García-Azorín (2022). "Cardio-Pulmonary Dysfunction Evaluation in Patients with Persistent Post-COVID-19 Headache." <u>Int J Environ Res Public Health</u> **19**(7).

Apple, A. C., A. Oddi, M. J. Peluso, B. M. Asken, T. J. Henrich, J. D. Kelly, S. J. Pleasure, S. G. Deeks, I. E. Allen, J. N. Martin, L. C. Ndhlovu, B. L. Miller, M. L. Stephens and J. Hellmuth (2022). "Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19." <u>Ann Clin Transl Neurol</u> 9(2): 221-226.

Arslan, N. G., Ş. Aksakal, İ. Yılmam and S. Görgün (2022). "VEGF, IL-17 and IgG4 levels of patients with lung sequelae in post-COVID-19 period." <u>Tuberk Toraks</u> **70**(2): 179-186.

Badenoch, J. B., E. R. Rengasamy, C. Watson, K. Jansen, S. Chakraborty, R. D. Sundaram, D. Hafeez, E. Burchill, A. Saini, L. Thomas, B. Cross, C. K. Hunt, I. Conti, S. Ralovska, Z. Hussain, M. Butler, T. A. Pollak, I. Koychev, B. D. Michael, H. Holling, T. R. Nicholson, J. P. Rogers and A. G. Rooney (2022). "Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis." <u>Brain Commun</u> 4(1): fcab297.

Berentschot, J. C., H. A. Drexhage, D. G. Aynekulu Mersha, A. J. M. Wijkhuijs, C. H. GeurtsvanKessel, M. P. G. Koopmans, J. J. C. Voermans, R. W. Hendriks, N. M. A. Nagtzaam, M. de Bie, M. H. Heijenbrok-Kal, L. M. Bek, G. M. Ribbers, R. J. G. van den Berg-Emons, J. G. J. V. Aerts, W. A. Dik and M. E. Hellemons (2023). "Immunological profiling in long COVID: overall low grade inflammation and T-lymphocyte senescence and increased monocyte activation correlating with increasing fatigue severity." <u>Frontiers in Immunology</u> 14.

Berezhnoy, G., R. Bissinger, A. Liu, C. Cannet, H. Schäfer, K. Kienzle, M. Bitzer, H. Häberle, S. Göpel, C. Trautwein and Y. Singh (2023). "Maintained imbalance of triglycerides, apolipoproteins, energy metabolites and cytokines in long-term COVID-19 syndrome patients." Frontiers in Immunology 14.

Cervia, C., Y. Zurbuchen, P. Taeschler, T. Ballouz, D. Menges, S. Hasler, S. Adamo, M. E. Raeber, E. Bächli, A. Rudiger, M. Stüssi-Helbling, L. C. Huber, J. Nilsson, U. Held, M. A. Puhan and O. Boyman (2022). "Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome." Nature Communications **13**(1): 446.

Closhen, D., B. Bender, H. J. Luhmann and C. R. Kuhlmann (2010). "CRP-induced levels of oxidative stress are higher in brain than aortic endothelial cells." <u>Cytokine</u> **50**(2): 117-120.

Cohen, J. (2013). Statistical power analysis for the behavioral sciences, Routledge.

Colarusso, C., A. Maglio, M. Terlizzi, C. Vitale, A. Molino, A. Pinto, A. Vatrella and R. Sorrentino (2021). "Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN- $\beta$  but Higher Levels of IL-1 $\alpha$  and TGF- $\beta$ ." Biomedicines **9**(12).

Corrêa, H. L., L. A. Deus, T. B. Araújo, A. L. Reis, C. E. N. Amorim, A. B. Gadelha, R. L. Santos, F. S. Honorato, D. Motta-Santos, C. Tzanno-Martins, R. V. P. Neves and T. S. Rosa (2022). "Phosphate and IL-10 concentration as predictors of long-covid in hemodialysis patients: A Brazilian study." <u>Frontiers in Immunology</u> **13**.

Cumpston, M., T. Li, M. J. Page, J. Chandler, V. A. Welch, J. P. Higgins and J. Thomas (2019). "Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions." <u>Cochrane Database Syst Rev</u> **10**(10.1002): 14651858.

Dan, J. M., J. Mateus, Y. Kato, K. M. Hastie, E. D. Yu, C. E. Faliti, A. Grifoni, S. I. Ramirez, S. Haupt, A. Frazier, C. Nakao, V. Rayaprolu, S. A. Rawlings, B. Peters, F. Krammer, V. Simon, E. O. Saphire, D. M. Smith, D. Weiskopf, A. Sette and S. Crotty (2021). "Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection." Science **371**(6529).

Dasari, N., A. Banga, N. Pallipamu, T. Pandit, R. Pandit and R. Adhikari (2022). "A Case of Deep Vein Thrombosis After Recovery From COVID-19 and Its Association With Elevated D-dimers." Cureus **14**(10): e29859.

Di Nicola, V. and D. Stoyanov (2021). Psychiatric Nosology Revisited: At the Crossroads of Psychology and Medicine. <u>Psychiatry in Crisis: At the Crossroads of Social Sciences</u>, the <u>Humanities</u>, and <u>Neuroscience</u>. V. Di Nicola and D. Stoyanov. Cham, Springer International Publishing: 31-41.

Díaz-Salazar, S., R. Navas, L. Sainz-Maza, P. Fierro, M. Maamar, A. Artime, H. Basterrechea, B. Petitta, S. Pini, J. M. Olmos, C. Ramos, E. Pariente and J. L. Hernández (2022). "Blood group O is associated with post-COVID-19 syndrome in outpatients with a low comorbidity index." <u>Infect Dis (Lond)</u> **54**(12): 897-908.

Dugani, P., A. Mehta, S. Furtado, R. Pradeep, M. Javali, P. Acharya, V. Thyagaraj and R. Srinivasa (2022). "Spectrum of neurological manifestations among acute COVID-19 and long COVID-19—A retrospective observational study." <u>Romanian Journal of Neurology</u> **21**(2).

Durstenfeld, M. S., M. J. Peluso, J. D. Kelly, S. Win, S. Swaminathan, D. Li, V. M. Arechiga, V. Zepeda, K. Sun, S. Shao, C. Hill, M. I. Arreguin, S. Lu, R. Hoh, V. Tai, A. Chenna, B. C. Yee, J. W. Winslow, C. J. Petropoulos, J. Kornak, T. J. Henrich, J. N. Martin, S. G. Deeks and P. Y. Hsue (2022). "Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection." JCI Insight 7(10).

Elizabeth, S. C. P. W., B. M. Thomas, R. H. Harry, C. Mayte, S. S. Kevin, P. Vicente and M. S. Adam (2022). "Plasma cytokine levels reveal deficiencies in IL-8 and gamma interferon in Long-COVID." medRxiv: 2022.2010.2003.22280661.

Elke, W., X. H. Alvin, D. G. v. W. Hugo, V. Anouk, P. Lisa van, M. Irma, M. v. L. Ester, G. v. d. A. Joost, D. d. J. Menno, N. Pythia, P. Maria, A. K. Neeltje, J. d. B. Godelieve and R. S. G. the (2023). "Inflammatory profiles are associated with long COVID up to 6 months after illness onset: a prospective cohort study of individuals with mild to critical COVID-19." medRxiv: 2023.2006.2014.23291395.

Espín, E., C. Yang, C. P. Shannon, S. Assadian, D. He and S. J. Tebbutt (2023). "Cellular and molecular biomarkers of long COVID: a scoping review." <u>eBioMedicine</u> **91**.

Fan, B. E., S. W. Wong, C. L. L. Sum, G. H. Lim, B. P. Leung, C. W. Tan, K. Ramanathan, R. Dalan, C. Cheung, X. R. Lim, M. S. Sadasiv, D. C. Lye, B. E. Young, E. S. Yap and Y. W. Chia (2022). "Hypercoagulability, endotheliopathy, and inflammation approximating 1 □ year after recovery: Assessing the long-term outcomes in COVID-19 patients." Am J Hematol 97(7): 915-923.

Fernández-de-Las-Peñas, C., P. Ryan-Murua, J. Rodríguez-Jiménez, M. Palacios-Ceña, L. Arendt-Nielsen and J. Torres-Macho (2022). "Serological Biomarkers at Hospital Admission Are Not Related to Long-Term Post-COVID Fatigue and Dyspnea in COVID-19 Survivors." Respiration **101**(7): 658-665.

Ferrando, S. J., R. Dornbush, S. Lynch, S. Shahar, L. Klepacz, C. L. Karmen, D. Chen, S. A. Lobo and D. Lerman (2022). "Neuropsychological, Medical, and Psychiatric Findings After Recovery From Acute COVID-19: A Cross-sectional Study." <u>J Acad Consult Liaison Psychiatry</u> **63**(5): 474-484.

Flaskamp, L., C. Roubal, S. Uddin, F. Sotzny, C. Kedor, S. Bauer, C. Scheibenbogen and M. Seifert (2022). "Serum of Post-COVID-19 Syndrome Patients with or without ME/CFS Differentially Affects Endothelial Cell Function In Vitro." Cells 11(15).

Fogarty, H., S. E. Ward, L. Townsend, E. Karampini, S. Elliott, N. Conlon, J. Dunne, R. Kiersey, A. Naughton, M. Gardiner, M. Byrne, C. Bergin, J. M. O'Sullivan, I. Martin-Loeches, P. Nadarajan, C. Bannan, P. W. Mallon, G. F. Curley, R. J. S. Preston, A. M. Rehill, R. I. Baker, C. N. Cheallaigh and J. S. O'Donnell (2022). "Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction." J Thromb Haemost **20**(10): 2429-2438.

Galán, M., L. Vigón, D. Fuertes, M. A. Murciano-Antón, G. Casado-Fernández, S. Domínguez-Mateos, E. Mateos, F. Ramos-Martín, V. Planelles, M. Torres, S. Rodríguez-Mora, M. R. López-Huertas and M. Coiras (2022). "Persistent Overactive Cytotoxic Immune Response in a Spanish Cohort of Individuals With Long-COVID: Identification of Diagnostic Biomarkers." Front Immunol 13: 848886.

Gameil, M. A., R. E. Marzouk, A. H. Elsebaie and S. E. Rozaik (2021). "Long-term clinical and biochemical residue after COVID-19 recovery." Egypt Liver J 11(1): 74.

García-Abellán, J., M. Fernández, S. Padilla, J. A. García, V. Agulló, V. Lozano, N. Ena, L. García-Sánchez, F. Gutiérrez and M. Masiá (2022). "Immunologic phenotype of patients with long-COVID syndrome of 1-year duration." Frontiers in Immunology 13.

Garcia-Gasalla, M., M. Berman-Riu, A. Rodriguez, A. Iglesias, P. A. Fraile-Ribot, N. Toledo-Pons, E. Pol-Pol, A. Ferré-Beltrán, F. Artigues-Serra, M. L. Martin-Pena, J. Pons, J. Murillas, A. Oliver, M. Riera and J. M. Ferrer (2023). "Elevated complement C3 and

increased CD8 and type 1 helper lymphocyte T populations in patients with post-COVID-19 condition." Cytokine **169**: 156295.

Gomes, S. M. R., A. C. d. S. Brito, W. F. P. Manfro, M. Ribeiro-Alves, R. S. d. A. Ribeiro, M. S. da Cal, V. d. C. Lisboa, D. P. B. d. Abreu, L. d. R. Castilho, L. C. d. M. S. Porto, T. T. Mafort, A. J. Lopes, S. A. G. da Silva, P. M. L. Dutra and L. S. Rodrigues (2023). "High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients." PLOS ONE **18**(4): e0283983.

Hsuchou, H., A. J. Kastin, P. K. Mishra and W. Pan (2012). "C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation." <u>Cellular physiology</u> and biochemistry **30**(5): 1109-1119.

Johannes, J. K., B. Andrea, H. Gerhard, M. M.-M. Samuel, F. Tobias, K. Anna, H. Marlene, S. Tarik, S. Lukas, R. Birgit, C. G. Marlene, S. Andreas, H. Ena, S. Doreen, G. Gerhard, G. Mariann, G. S. Klaus and G. Christopher (2022). "Multi-omics provide evidence for an anti-inflammatory immune signature and metabolic alterations in patients with Long COVID Syndrome – an exploratory study." <a href="mailto:medRxiv:2022.2007.2011.22277499">medRxiv:2022.2007.2011.22277499</a>.

Julia, S.-K., S. Stephan, F. Svenja, O. Veronica, G. Eva, P. Claire, G. Leonard, B. Isabel, W. Nikolas, I. M. A. Mohamed, I. Gerardo, R. Michael, B. Christopher, P. Anna, V. Elisabeth, H. Michael, A. Kristina, S. Hans Christian, P. Michael, S. Ulrich, B. Johannes, R. Julia, C. the Post Covid and g. KoCo19 study (2023). "Persistent immune abnormalities discriminate post-COVID syndrome from convalescence." <a href="mailto:medRxiv:2023.2005.2002.23289345">medRxiv:2023.2005.2002.23289345</a>.

Kelly, A. G., L. H. Sonya, F. Yuriko, Z. Xianming, B. Sheriza, G. A. Alison, H. Feben, S. David, R. Jessica, R. Malathi, L. Oliver, E. F. Reinaldo, U. P. Eshan, R. B. Owen, S. Shmuel, R. C. Edward, S. C. Judith, M. G. Jonathan, M. Barry, N. F. Donald, L. H. Laura, A. H. Moises, L. Adam, S. M. Giselle, P. Bela, H. P. James, S. R. Jay, G. S. Catherine, A. Shweta, G. Thomas, K. Seble, E. B. Janis, L. Karen, A. M. Nichol, L. G. Amy, D. Piyali, L. K. Sabra, P. Andrew, C. Arturo, M. B. Evan, H. Daniel, A. R. T. Aaron, J. S. David and C.-C. the (2023). "Early Treatment, Inflammation and Post-COVID Conditions." medRxiv: 2023.2002.2013.23285855.

Kovarik, J. J., A. Bileck, G. Hagn, S. M. Meier-Menches, T. Frey, A. Kaempf, M. Hollenstein, T. Shoumariyeh, L. Skos, B. Reiter, M. C. Gerner, A. Spannbauer, E. Hasimbegovic, D. Schmidl, G. Garhöfer, M. Gyöngyösi, K. G. Schmetterer and C. Gerner (2023). "A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome." <u>iScience</u> **26**(1): 105717.

Kruger, A., M. Vlok, S. Turner, C. Venter, G. J. Laubscher, D. B. Kell and E. Pretorius (2022). "Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system." <u>Cardiovasc Diabetol</u> **21**(1): 190.

Kuchler, T., R. Günthner, A. Ribeiro, R. Hausinger, L. Streese, A. Wöhnl, V. Kesseler, J. Negele, T. Assali, J. Carbajo-Lozoya, M. Lech, H. Schneider, K. Adorjan, H. C. Stubbe, H. Hanssen, K. Kotilar, B. Haller, U. Heemann and C. Schmaderer (2023). "Persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation." <u>Angiogenesis</u> **26**(4): 547-563.

Kuhlmann, C. R., L. Librizzi, D. Closhen, T. Pflanzner, V. Lessmann, C. U. Pietrzik, M. de Curtis and H. J. Luhmann (2009). "Mechanisms of C-reactive protein-induced bloodbrain barrier disruption." Stroke **40**(4): 1458-1466.

Littlefield, K. M., R. O. Watson, J. M. Schneider, C. P. Neff, E. Yamada, M. Zhang, T. B. Campbell, M. T. Falta, S. E. Jolley, A. P. Fontenot and B. E. Palmer (2022). "SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2." <u>PLoS Pathog</u> **18**(5): e1010359.

Loretelli, C., A. Abdelsalam, F. D'Addio, M. Ben Nasr, E. Assi, V. Usuelli, A. Maestroni, A. J. Seelam, E. Ippolito, S. Di Maggio, L. Loreggian, D. Radovanovic, C. Vanetti, J. Yang, B. El Essawy, A. Rossi, I. Pastore, L. Montefusco, M. E. Lunati, A. M. Bolla, M. Biasin, S. Antinori, P. Santus, A. Riva, G. V. Zuccotti, M. Galli, S. Rusconi and P. Fiorina (2021). "PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response." JCI Insight 6(24).

Maes, M. (2009). "Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms." <u>Current Opinion in Psychiatry</u> **22**(1).

Maes, M., H. T. Al-Rubaye, A. F. Almulla, D. S. Al-Hadrawi, K. Stoyanova, M. Kubera and H. K. Al-Hakeim (2022) "Lowered Quality of Life in Long COVID Is Predicted by Affective Symptoms, Chronic Fatigue Syndrome, Inflammation and Neuroimmunotoxic Pathways." <u>International Journal of Environmental Research and Public Health</u> **19** DOI: 10.3390/ijerph191610362.

Maes, M. and A. F. Carvalho (2018). "The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder." Mol Neurobiol **55**(12): 8885-8903.

Maes, M., I. Mihaylova, M. Kubera and K. Ringel (2012). "Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression." <u>Progress in Neuro-Psychopharmacology and Biological Psychiatry</u> **36**(1): 169-175.

Maes, M., M. Rachayon, K. Jirakran, P. Sodsai, S. Klinchanhom, M. Debnath, A. Basta-Kaim, M. Kubera, A. F. Almulla and A. Sughondhabirom (2022). "Adverse Childhood Experiences Predict the Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles." Cells **11**(9).

Maes, M., M. Rachayon, K. Jirakran, P. Sodsai, S. Klinchanhom, P. Gałecki, A. Sughondhabirom and A. Basta-Kaim (2022). "The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach." Cells 11(7).

Maes, M., K. Ringel, M. Kubera, G. Anderson, G. Morris, P. Galecki and M. Geffard (2013). "In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation." Journal of Affective Disorders **150**(2): 223-230.

Maes, M., F. N. M. Twisk, M. Kubera and K. Ringel (2012). "Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin." <u>Journal of Affective Disorders</u> **136**(3): 933-939.

Magdy, R., R. A. Eid, W. Fathy, M. M. Abdel-Aziz, R. E. Ibrahim, A. Yehia, M. S. Sheemy and M. Hussein (2022). "Characteristics and Risk Factors of Persistent Neuropathic Pain in Recovered COVID-19 Patients." <u>Pain Med</u> **23**(4): 774-781.

Martone, A. M., M. Tosato, F. Ciciarello, V. Galluzzo, M. B. Zazzara, C. Pais, G. Savera, R. Calvani, E. Marzetti, M. C. Robles, M. Ramirez and F. Landi (2022). "Sarcopenia as potential biological substrate of long COVID-19 syndrome: prevalence, clinical features, and risk factors." J Cachexia Sarcopenia Muscle **13**(4): 1974-1982.

Meisinger, C., Y. Goßlau, T. D. Warm, V. Leone, A. Hyhlik-Dürr, J. Linseisen and I. Kirchberger (2022). "Post-COVID-19 Fatigue and SARS-CoV-2 Specific Humoral and T-Cell Responses in Male and Female Outpatients." Frontiers in Immunology 13.

Melhorn, J., A. Alamoudi, A. J. Mentzer, E. Fraser, A. Fries, M. P. Cassar, A. Kwok, J. C. Knight, B. Raman, N. P. Talbot and N. Petousi (2023). "Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection." Frontiers in Medicine 10.

Meltendorf, S., K. Vogel, C. Thurm, F. Prätsch, A. Reinhold, J. Färber, H. G. Heuft, A. J. Kaasch, T. Hachenberg, S. Weinzierl, B. Schraven, D. Reinhold, M. C. Brunner-Weinzierl and H. Lingel (2022). "IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination." <u>Eur J Immunol</u> **52**(12): 1972-1979.

Mitrović-Ajtić, O., D. Đikić, T. Subotički, S. Bižić-Radulović, B. Beleslin-Čokić, T. Dragojević, E. Živković, S. Miljatović, M. Vukotić, D. Stanisavljević, J. Santibanez and V. P. Čokić (2023) "Sex Differences and Cytokine Profiles among Patients Hospitalized for COVID-19 and during Their Recovery: The Predominance of Adhesion Molecules in Females and Oxidative Stress in Males." <u>Vaccines</u> 11 DOI: 10.3390/vaccines11101560.

Montefusco, L., M. Ben Nasr, F. D'Addio, C. Loretelli, A. Rossi, I. Pastore, G. Daniele, A. Abdelsalam, A. Maestroni, M. Dell'Acqua, E. Ippolito, E. Assi, V. Usuelli, A. J.

Seelam, R. M. Fiorina, E. Chebat, P. Morpurgo, M. E. Lunati, A. M. Bolla, G. Finzi, R. Abdi, J. V. Bonventre, S. Rusconi, A. Riva, D. Corradi, P. Santus, M. Nebuloni, F. Folli, G. V. Zuccotti, M. Galli and P. Fiorina (2021). "Acute and long-term disruption of

G. V. Zuccotti, M. Galli and P. Fiorina (2021). "Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection." Nat Metab 3(6): 774-785.

Nádasdi, Á., G. Sinkovits, I. Bobek, B. Lakatos, Z. Förhécz, Z. Z. Prohászka, M. Réti, M. Arató, G. Cseh, T. Masszi, B. Merkely, P. Ferdinandy, I. Vályi-Nagy, Z. Prohászka and G. Firneisz (2022). "Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients." Biomark Med 16(5): 317-330.

Neves, P. F., J. A. Quaresma, M. A. Queiroz, C. C. Silva, E. V. Maia, J. S. Oliveira, C. M. Neves, S. D. Mendonça, A. S. Falcão, G. S. Melo, I. B. Santos, J. R. Sousa, E. J. Santos, P. F. Vasconcelos, A. C. Vallinoto and L. F. Falcão (2023) "Imbalance of Peripheral Temperature, Sympathovagal, and Cytokine Profile in Long COVID." Biology 12 DOI: 10.3390/biology12050749.

O'Mahoney, L. (2023). The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine 55, 101762, Article.

Ong, S. W. X., S. W. Fong, B. E. Young, Y. H. Chan, B. Lee, S. N. Amrun, R. S. Chee, N. K. Yeo, P. Tambyah, S. Pada, S. Y. Tan, Y. Ding, L. Renia, Y. S. Leo, L. F. P. Ng and D. C. Lye (2021). "Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients." Open Forum Infect Dis 8(6): ofab156.

Opsteen, S., J. K. Files, T. Fram and N. Erdmann (2023). "The role of immune activation and antigen persistence in acute and long COVID." <u>J Investig Med</u> **71**(5): 545-562.

Page, M. J., J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mulrow, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, R. Chou, J. Glanville, J. M. Grimshaw, A. Hróbjartsson, M. M. Lalu, T. Li, E. W. Loder, E. Mayo-Wilson, S. McDonald, L. A. McGuinness, L. A. Stewart, J. Thomas, A. C. Tricco, V. A. Welch, P. Whiting and D. Moher (2021). "The PRISMA 2020 statement: An updated guideline for reporting systematic reviews." PLOS Medicine 18(3): e1003583.

Park, J., L. S. Dean, B. Jiyarom, L. M. Gangcuangco, P. Shah, T. Awamura, L. L. Ching, V. R. Nerurkar, D. C. Chow, F. Igno, C. M. Shikuma and G. Devendra (2023). "Elevated circulating monocytes and monocyte activation in COVID-19 convalescent individuals." Frontiers in Immunology **14**.

Patel, M. A., M. J. Knauer, M. Nicholson, M. Daley, L. R. Van Nynatten, C. Martin, E. K. Patterson, G. Cepinskas, S. L. Seney, V. Dobretzberger, M. Miholits, B. Webb and D. D. Fraser (2022). "Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism." Molecular Medicine 28(1): 122.

Patra, T. and R. Ray (2022). "Bystander effect of SARS-CoV-2 spike protein on human monocytic THP-1 cell activation and initiation of prothrombogenic stimulus representing severe COVID-19." J Inflamm (Lond) **19**(1): 28.

Patterson, B. K., J. Guevara-Coto, R. Yogendra, E. B. Francisco, E. Long, A. Pise, H. Rodrigues, P. Parikh, J. Mora and R. A. Mora-Rodríguez (2021). "Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning." Frontiers in Immunology 12.

Peluso, M. J., A. N. Deitchman, L. Torres, N. S. Iyer, S. E. Munter, C. C. Nixon, J. Donatelli, C. Thanh, S. Takahashi, J. Hakim, K. Turcios, O. Janson, R. Hoh, V. Tai, Y. Hernandez, E. A. Fehrman, M. A. Spinelli, M. Gandhi, L. Trinh, T. Wrin, C. J. Petropoulos, F. T. Aweeka, I. Rodriguez-Barraquer, J. D. Kelly, J. N. Martin, S. G. Deeks, B. Greenhouse, R. L. Rutishauser and T. J. Henrich (2021). "Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms." Cell Rep 36(6): 109518.

Peluso, M. J., S. Lu, A. F. Tang, M. S. Durstenfeld, H. E. Ho, S. A. Goldberg, C. A. Forman, S. E. Munter, R. Hoh, V. Tai, A. Chenna, B. C. Yee, J. W. Winslow, C. J. Petropoulos, B. Greenhouse, P. W. Hunt, P. Y. Hsue, J. N. Martin, J. Daniel Kelly, D. V. Glidden, S. G. Deeks and T. J. Henrich (2021). "Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection." J Infect Dis 224(11): 1839-1848.

Peluso, M. J., H. M. Sans, C. A. Forman, A. N. Nylander, H.-e. Ho, S. Lu, S. A. Goldberg, R. Hoh, V. Tai, S. E. Munter, A. Chenna, B. C. Yee, J. W. Winslow, C. J. Petropoulos, J. N. Martin, J. D. Kelly, M. S. Durstenfeld, P. Y. Hsue, P. W. Hunt, M. Greene, F. C. Chow, J. Hellmuth, T. J. Henrich, D. V. Glidden and S. G. Deeks (2022). "Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection." Neurology Neuroimmunology & Neuroinflammation 9(5): e200003.

Petrella, C., R. Nenna, L. Petrarca, F. Tarani, R. Paparella, E. Mancino, G. Di Mattia, M. G. Conti, L. Matera, E. Bonci, F. M. Ceci, G. Ferraguti, F. Gabanella, C. Barbato, M. G. Di Certo, L. Cavalcanti, A. Minni, F. Midulla, L. Tarani and M. Fiore (2022). "Serum

NGF and BDNF in Long-COVID-19 Adolescents: A Pilot Study." <u>Diagnostics (Basel)</u> **12**(5).

Phetsouphanh, C., D. R. Darley, D. B. Wilson, A. Howe, C. M. L. Munier, S. K. Patel, J. A. Juno, L. M. Burrell, S. J. Kent, G. J. Dore, A. D. Kelleher and G. V. Matthews (2022). "Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection." Nat Immunol 23(2): 210-216.

Prashar, J. (2023). "Long Covid: conceptualizing the challenges for public health." Journal of Public Health **45**(3): 771-779.

Premraj, L., N. V. Kannapadi, J. Briggs, S. M. Seal, D. Battaglini, J. Fanning, J. Suen, C. Robba, J. Fraser and S. M. Cho (2022). "Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis." <u>J Neurol</u> Sci **434**: 120162.

Queiroz, M. A. F., P. F. M. d. Neves, S. S. Lima, J. d. C. Lopes, M. K. d. S. Torres, I. M. V. C. Vallinoto, C. D. A. Bichara, E. F. d. Santos, M. T. F. M. de Brito, A. L. S. da Silva, M. d. M. Leite, F. P. da Costa, M. d. N. d. S. d. A. Viana, F. B. B. Rodrigues, K. M. L. de Sarges, M. H. D. Cantanhede, R. da Silva, C. N. C. Bichara, A. V. S. v. d. Berg, A. d. O. L. Veríssimo, M. d. S. Carvalho, D. F. Henriques, C. P. d. Santos, J. A. L. Nunes, I. B. Costa, G. M. R. Viana, F. R. O. Carneiro, V. R. d. C. M. Palacios, J. A. S. Quaresma, I. Brasil-Costa, E. J. M. d. Santos, L. F. M. Falcão and A. C. R. Vallinoto (2022). "Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome." Frontiers in Cellular and Infection Microbiology 12.

Saxena, R., S. Saxena, A. P. Singh, V. Singh and J. Batra (2022). "Oxi-Inflammatory Stress and Biomolecular Deterioration: A Mysterious Convergence in Post COVID Patients." Journal of Pharmaceutical Negative Results: 555-561.

Schultheiß, C., E. Willscher, L. Paschold, C. Gottschick, B. Klee, L. Bosurgi, J. Dutzmann, D. Sedding, T. Frese, M. Girndt, J. I. Höll, M. Gekle, R. Mikolajczyk and M. Binder (2023). "Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19." J Med Virol **95**(1): e28364.

Schultheiß, C., E. Willscher, L. Paschold, C. Gottschick, B. Klee, S. S. Henkes, L. Bosurgi, J. Dutzmann, D. Sedding, T. Frese, M. Girndt, J. I. Höll, M. Gekle, R. Mikolajczyk and M. Binder (2022). "The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19." Cell Rep Med 3(6): 100663.

Scott, N. A., L. Pearmain, S. B. Knight, O. Brand, D. J. Morgan, C. Jagger, S. Harbach, S. Khan, H. A. Shuwa, M. Franklin, V. Kästele, T. Williams, I. Prise, F. A. McClure, P. Hackney, L. Smith, M. Menon, J. E. Konkel, C. Lawless, J. Wilson, A. G. Mathioudakis, S. C. Stanel, A. Ustianowski, G. Lindergard, S. Brij, N. Diar Bakerly, P. Dark, C. Brightling, P. Rivera-Ortega, G. M. Lord, A. Horsley, K. Piper Hanley, T. Felton, A. Simpson, J. R. Grainger, T. Hussell and E. R. Mann (2023). "Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID." <u>Eur Respir J 61</u>(5).

Sibila, O., L. Perea, N. Albacar, J. Moisés, T. Cruz, N. Mendoza, B. Solarat, G. Lledó, G. Espinosa, J. A. Barberà, J. R. Badia, A. Agustí, J. Sellarés and R. Faner (2022). "Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with

reduced lung diffusing capacity six months after hospital discharge." Respiratory Research 23(1): 37.

Siekacz, K., A. Kumor-Kisielewska, J. Miłkowska-Dymanowska, M. Pietrusińska, K. Bartczak, S. Majewski, A. Stańczyk, W. J. Piotrowski and A. J. Białas (2023). "Oxidative Biomarkers Associated with the Pulmonary Manifestation of Post-COVID-19 Complications." <u>J Clin Med</u> **12**(13).

Simone, T., A. N. Caitlin, J. U. Thomas, K. Arneaux, V. Chantelle, L. Gert Jacobus, M. A. Khan, B. K. Douglas and P. Etheresia (2022). "Increased levels of inflammatory molecules in blood of Long COVID patients point to thrombotic endotheliitis." <a href="mailto:medRxiv">medRxiv</a>: 2022.2010.2013.22281055.

Sommen, S. L., L. B. Havdal, J. Selvakumar, G. Einvik, T. M. Leegaard, F. Lund-Johansen, A. E. Michelsen, T. E. Mollnes, T. Stiansen-Sonerud, T. Tjade, V. B. B. Wyller and L. L. Berven (2023). "Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19." Frontiers in Immunology **13**.

Soni, P., A. Soni, P. Singh and M. Verma (2021). "Association of depression with il-6 and crp levels among covid recovered patients: A hospital based case control study." International Journal of Toxicological and Pharmacological Research: 23-27.

Sreenivas, N., M. Maes, H. Padmanabha, A. Dharmendra, P. Chakkera, S. Paul Choudhury, F. Abdul, T. Mullapudi, V. K. Gowda, M. Berk, J. Vijay Sagar Kommu and M. Debnath (2024). "Comprehensive immunoprofiling of neurodevelopmental disorders suggests three distinct classes based on increased neurogenesis, Th-1 polarization or IL-1 signaling." <u>Brain Behav Immun</u> **115**: 505-516.

Stavileci, B., E. Özdemir, B. Özdemir, E. Ereren and M. Cengiz (2022). "De-novo development of fragmented QRS during a six-month follow-up period in patients with COVID-19 disease and its cardiac effects." Journal of Electrocardiology **72**: 44-48.

Stepanova, N., L. Korol, L. Snisar, A. Rysyev, T. Ostapenko, V. Marchenko, O. Belousova, O. Popova, N. Malashevska and M. Kolesnyk (2023). "Long-COVID sequelae are associated with oxidative stress in hemodialysis patients." <u>Ukrainian Journal</u> of Nephrology and Dialysis(1 (77)): 31-39.

Strong, M. J. (2023). "SARS-CoV-2, aging, and Post-COVID-19 neurodegeneration." Journal of Neurochemistry **165**(2): 115-130.

Sun, B., N. Tang, M. J. Peluso, N. S. Iyer, L. Torres, J. L. Donatelli, S. E. Munter, C. C. Nixon, R. L. Rutishauser, I. Rodriguez-Barraquer, B. Greenhouse, J. D. Kelly, J. N. Martin, S. G. Deeks, T. J. Henrich and L. Pulliam (2021). "Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations." Cells 10(2).

Taeschler, P., S. Adamo, Y. Deng, C. Cervia, Y. Zurbuchen, S. Chevrier, M. E. Raeber, S. Hasler, E. Bächli, A. Rudiger, M. Stüssi-Helbling, L. C. Huber, B. Bodenmiller, O. Boyman and J. Nilsson (2022). "T-cell recovery and evidence of persistent immune activation 12 □months after severe COVID-19." <u>Allergy</u> 77(8): 2468-2481.

Taha, S. I., S. F. Samaan, R. A. Ibrahim, E. M. El-Sehsah and M. K. Youssef (2021). "Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity?" <u>Eur Cytokine</u> Netw **32**(4): 83-88.

Teng, L., X. Song, M. Zhang, Y. Han, G. Chang, W. Chang and Z. Shen (2023). "The pattern of cytokines expression and dynamic changes of renal function at 6 months in patients with Omicron COVID-19." <u>J Med Virol</u> **95**(2): e28477.

Torres-Ruiz, J., J. Lomelín-Gascón, J. Lira Luna, A. S. Vargas- Castro, A. Pérez-Fragoso, M. Nuñez-Aguirre, B. Alcalá-Carmona, A. Absalón-Aguilar, J. T. Balderas-Miranda, J. L. Maravillas-Montero, N. R. Mejía-Domínguez, C. Núñez-Álvarez, L. Llorente, S. Romero-Ramírez, V. A. Sosa-Hernández, R. Cervantes-Díaz, G. Juárez-Vega, D. Meza-Sánchez, M. Rull-Gabayet, L. A. Martínez-Juárez, L. Morales, L. N. López-López, J. A. Negrete-Trujillo, J. A. Falcón-Lezama, R. R. Valdez-Vázquez, H. Gallardo-Rincón, R. Tapia-Conyer and D. Gómez-Martín (2023). "Novel clinical and immunological features associated with persistent post-acute sequelae of COVID-19 after six months of followup: a pilot study." Infectious Diseases 55(4): 243-254.

Townsend, L., A. H. Dyer, K. Jones, J. Dunne, A. Mooney, F. Gaffney, L. O'Connor, D.

Leavy, K. O'Brien, J. Dowds, J. A. Sugrue, D. Hopkins, I. Martin-Loeches, C. Ni Cheallaigh, P. Nadarajan, A. M. McLaughlin, N. M. Bourke, C. Bergin, C. O'Farrelly, C. Bannan and N. Conlon (2020). "Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection." PLoS One 15(11): e0240784.

Utrero-Rico, A., C. González-Cuadrado, M. Chivite-Lacaba, O. Cabrera-Marante, R. Laguna-Goya, P. Almendro-Vazquez, C. Díaz-Pedroche, M. Ruiz-Ruigómez, A. Lalueza, M. D. Folgueira, E. Vázquez, A. Quintas, M. J. Berges-Buxeda, M. Martín-Rodriguez, A. Dopazo, A. Serrano-Hernández, J. M. Aguado and E. Paz-Artal (2021). "Alterations in Circulating Monocytes Predict COVID-19 Severity and Include Chromatin Modifications Still Detectable Six Months after Recovery." Biomedicines 9(9).

Vasupanrajit, A., K. Jirakran, C. Tunvirachaisakul, M. Solmi and M. Maes (2022). "Inflammation and nitro-oxidative stress in current suicidal attempts and current suicidal ideation: a systematic review and meta-analysis." <u>Molecular Psychiatry</u> **27**(3): 1350-1361.

Vazquez-Alejo, E., L. Tarancon-Diez, M. S. Espinar-Buitrago, M. Genebat, A. Calderón, G. Pérez-Cabeza, E. Magro-Lopez, M. Leal and M. Muñoz-Fernández (2023). "Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study." J Clin Med **12**(10).

Ventura, M. T., M. Casciaro, S. Gangemi and R. Buquicchio (2017). "Immunosenescence in aging: between immune cells depletion and cytokines up-regulation." <u>Clin Mol Allergy</u> **15**: 21.

Vibholm, L. K., S. S. F. Nielsen, M. H. Pahus, G. S. Frattari, R. Olesen, R. Andersen, I. Monrad, A. H. F. Andersen, M. M. Thomsen, C. V. Konrad, S. D. Andersen, J. F. Højen, J. D. Gunst, L. Østergaard, O. S. Søgaard, M. H. Schleimann and M. Tolstrup (2021). "SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses." <a href="mailto:EBioMedicine"><u>EBioMedicine</u></a> 64: 103230.

Vojdani, A., A. F. Almulla, Z. Bo, K. A.-H. Hussein and M. Michael (2023). "Reactivation of herpesvirus type-6 and IgA/IgM-mediated responses to activin-A underpin Long COVID, including affective symptoms and chronic fatigue syndrome." <a href="mailto:medRxiv">medRxiv</a>: 2023.2007.2023.23293046.

Wallis, T. J. M., E. Heiden, J. Horno, B. Welham, H. Burke, A. Freeman, L. Dexter, A. Fazleen, A. Kong, C. McQuitty, M. Watson, S. Poole, N. J. Brendish, T. W. Clark, T. M. A. Wilkinson, M. G. Jones and B. G. Marshall (2021). "Risk factors for persistent

abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19." Respir Res 22(1): 157.

Wan, X., W. Wang, J. Liu and T. Tong (2014). "Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range." <u>BMC Medical</u> Research Methodology **14**(1): 135.

Wechsler, J. B., M. Butuci, A. Wong, A. P. Kamboj and B. A. Youngblood (2022). "Mast cell activation is associated with post-acute COVID-19 syndrome." <u>Allergy</u> **77**(4): 1288-1291.

Wiech, M., P. Chroscicki, J. Swatler, D. Stepnik, S. De Biasi, M. Hampel, M. Brewinska-Olchowik, A. Maliszewska, K. Sklinda, M. Durlik, W. Wierzba, A. Cossarizza and K. Piwocka (2022). "Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection." Frontiers in Immunology 13.

World Health Organization, W. (2021). "A clinical case definition of post COVID-19 condition by a Delphi consensus

#### 6 October." WHO.

Wu, X., K.-Q. Deng, C. Li, Z. Yang, H. Hu, H. Cai, C. Zhang, T. He, F. Zheng, H. Wang, X. A. Zhang, A. Caillon, Y. Yuan, X. Wang, H. Xu and Z. Lu (2021). "Cardiac Involvement in Recovered Patients From COVID-19: A Preliminary 6-Month Follow-Up Study." Frontiers in Cardiovascular Medicine 8.

Xu, J., J. Zheng, Y. Tan, J. Cai, Y. Xiang, H. Ling, Z. Li and Q. Bai (2023). "Longitudinal Observation of Immune Response for 23 Months in COVID-19 Convalescent Patients After Infection and Vaccination." <u>Viral Immunol</u> **36**(6): 389-400.

Yin, J.-X., Y. L. Agbana, Z.-S. Sun, S.-W. Fei, H.-Q. Zhao, X.-N. Zhou, J.-H. Chen and K. Kassegne (2023). "Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis." <u>Infectious Diseases of Poverty</u> **12**(1): 43.

Yong, S. J., A. Halim, M. Halim, S. Liu, M. Aljeldah, B. R. Al Shammari, S. Alwarthan, M. Alhajri, A. Alawfi, A. Alshengeti, F. Khamis, J. Alsalman, A. N. Alshukairi, N. A. Abukhamis, F. S. Almaghrabi, S. A. Almuthree, A. M. Alsulaiman, B. M. Alshehail, A. H. Alfaraj, S. A. Alhawaj, R. K. Mohapatra and A. A. Rabaan (2023). "Inflammatory and vascular biomarkers in post-COVID-19 syndrome: A systematic review and meta-analysis of over 20 biomarkers." Reviews in Medical Virology **33**(2): e2424.

Zhang, D., Y. Zhou, Y. Ma, P. Chen, J. Tang, B. Yang, H. Li, M. Liang, Y. Xue, Y. Liu, J. Zhang and X. Wang (2023). "Gut Microbiota Dysbiosis Correlates With Long COVID-19 at One-Year After Discharge." <u>J Korean Med Sci</u> **38**(15): e120.

Zhao, J., M. Schank, L. Wang, X. Dang, D. Cao, S. Khanal, L. N. T. Nguyen, Y. Zhang, X. Y. Wu, J. L. Adkins, B. J. Pelton, J. Zhang, S. Ning, M. E. Gazzar, J. P. Moorman and Z. Q. Yao (2022). "Plasma biomarkers for systemic inflammation in COVID-19 survivors." Proteomics Clin Appl **16**(5): e2200031.

**Table 1:** The outcomes and number of patients with Long COVID (LC) disease and healthy control along with the side of standardized mean difference (SMD) and the 95% confidence intervals with respect to zero SMD.

		Sid	e of 95% con	fidence inter	vals			Total
Outcome profiles	n studies	< 0	Overlap 0 and SMD < 0	Overlap 0 and SMD > 0	> 0	Patient Cases	Control Cases	Total number of participants
IRS/CIRS	37	0	12	19	6	1770	1854	3624
IRS	62	2	19	23	18	2795	2898	5693
CIRS	36	6	11	10	9	1709	1790	3499
M1/M2	41	1	17	21	2	1864	1942	3806
M1 Macrophage	68	2	19	25	22	3079	3084	6136
M2 Macrophage	40	5	14	10	11	1804	1878	3682
Th1/Th2	45	2	23	16	4	2156	2271	4427
Th1	45	4	14	16	11	2175	2245	4420
Th2	57	4	19	14	20	2638	2747	5383
Th17	55	3	16	14	22	2539	2622	5161
Neurotoxicity	62	8	20	12	22	2795	2898	5693
CRP	38	2	5	15	16	1933	2579	4512

M1 Macrophage: Interleukin (IL)-1β, IL-6, Tumor necrosis factor (TNF)-α, IL-12p70, IL-15, CCL2, CCL5, CXCL1, CXCL8, CXCL9, CXCL10 M2 Macrophage: IL-10, IL-4, IL-13, Vascular endothelial growth factor (VEGF), Platelet-derived growth factor (PDGF), Soluble interleukin-1 receptor antagonist (sIL-1RA)

T helper (Th)-1: IL-2, sIL-2R, interferon (IFN)-a, IFN-γ, IL-12p70, IL-16, TNF-α, TNF-β

**T helper (Th)-2:** IL-4, IL-5, IL-9, IL-13, IL-10, IL-6

**T helper (Th)-17:** IL-6, IL-17

IRS: IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, TNF- $\alpha$ , IL-12p70, IL-15, IL-16, IL-17, IL-18, CCL2, CCL3, CCL4, CCL5, CCL7, CCL11, CXCL1, CXCL8, CXCL9, CXCL10, IL-2, IFN- $\alpha$ , IFN- $\alpha$ , TNF- $\alpha$ 

medRxiv preprint doi: https://doi.org/10.1101/2024.02.08.24302516; this version posted February 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

CIRS: IL-4, IL-10, sIL-1RA, Soluble interleukin-2 receptor (sIL-2R)

**Neurotoxicity:** IL-1β, IL-6, TNF-α, TRAIL, IL-2, IFN-γ, IL-12p70, IL-16, IL-17, CCL2, CCL3, CCL5, CCL11, CXCL1, CXCL8, CXCL10, GM-CSF, M-CSF IRS: Immune-response system, CIRS: Compensatory immune-response system, M: Macrophage, Th: T helper, CRP: C-reactive protein,

**Table 2**: Results of meta-analysis performed on several outcomes (Inflammatory profiles and solitary cytokines) variables with.

Outcome feature sets	n	Groups	SMD	95% CI	Z	р	Q	df	р	I <sup>2</sup> (%)	$ au^2$	T
IRS/CIRS	37	Overall	0.126	0.024;0.228	2.421	0.015	58.862	36	0.009	38.840	0.032	0.180
IRS	62	Overall	0.247	0.130;0.363	4.150	< 0.0001	218.455	61	< 0.0001	72.077	0.139	0.372
CIRS	36	Overall	0.070	-0.110;0.250	0.760	0.447	181.135	35	< 0.0001	80.677	0.214	0.463
M1/M2	41	Overall	0.061	-0.061;0.183	0.982	0.326	98.357	40	< 0.0001	59.332	0.078	0.280
M1 Macrophage	68	Overall	0.327	0.200;0.454	5.041	< 0.0001	311.920	67	< 0.0001	78.520	0.200	0.447
M2 Macrophage	40	Overall	0.125	-0.052;0.301	1.387	0.165	204.570	39	< 0.0001	80.936	0.229	0.478
Th1/Th2	45	Overall	0.027	-0.088;0.124	0.455	0.649	113.959	44	< 0.0001	61.390	0.080	0.284
Th1	45	Overall	0.230	0.073;0.388	2.869	0.004	218.508	44	< 0.0001	79.863	0.203	0.451
Th2	57	Overall	0.241	0.103;0.380	3.422	0.001	270.383	56	< 0.0001	79.289	0.201	0.448
Th17	55	Overall	0.316	0.163;0.468	4.067	< 0.0001	312.028	54	< 0.0001	82.694	0.250	0.500
Neurotoxicity	62	Overall	0.260	0.143;0.377	4.347	< 0.0001	220.506	61	< 0.0001	72.336	0.141	0.375
CRP	38	Overall	0.507	0.299;0.715	4.779	< 0.0001	355.004	37	< 0.0001	89.578	0.365	0.604

M1 Macrophage: Interleukin (IL)-1β, IL-6, Tumor necrosis factor (TNF)-α, IL-12p70, IL-15, CCL2, CCL5, CXCL1, CXCL8, CXCL9, CXCL10 M2 Macrophage: IL-10, IL-4, IL-13, Vascular endothelial growth factor (VEGF), Platelet-derived growth factor (PDGF), Soluble interleukin-1 receptor antagonist (sIL-1RA)

T helper (Th)-1: IL-2, sIL-2R, interferon (IFN)-a, IFN-γ, IL-12p70, IL-16, TNF-α, TNF-β

**T helper (Th)-2:** IL-4, IL-5, IL-9, IL-13, IL-10, IL-6

**T helper (Th)-17:** IL-6, IL-17

**IRS:** IL-1α, IL-1β, IL-6, TNF-α, IL-12p70, IL-15, IL-16, IL-17, IL-18, CCL2, CCL3, CCL4, CCL5, CCL7, CCL11, CXCL1, CXCL8, CXCL9, CXCL10, IL-2, IFN-α, IFN-γ, TNF-α, TNF-β, Tumor necrosis factor related apoptosis-inducing ligand (TRAIL), Granulocyte-macrophage colony-stimulating factor (GM-CSF), Macrophage colony-stimulating factor (M-CSF), Granulocyte colony-stimulating factor (G-CSF), Stem cell growth factor-beta (SCGF).

CIRS: IL-4, IL-10, sIL-1RA, Soluble interleukin-2 receptor (sIL-2R)

**Neurotoxicity:** IL-1β, IL-6, TNF-α, TRAIL, IL-2, IFN-γ, IL-12p70, IL-16, IL-17, CCL2, CCL3, CCL5, CCL11, CXCL1, CXCL8, CXCL10, GM-CSF, M-CSF IRS: Immune-response system, CIRS: Compensatory immune-response system, M: Macrophage, Th: T helper, CRP: C-reactive protein,

**Table 3:** Results on publication bias.

Outcome feature sets	Fail safe n	Z Kendall's τ	p	Egger's t test (df)	p	Missing studies (side)	After Adjusting
IRS/CIRS	3.093	0.640	0.260	0.362(35)	0.359	3 (Right)	0.156 (0.051;0.261)
IRS	7.489	0.376	0.353	1.303(60)	0.098	7 (Right)	0.345 (0.222;0.468)
CIRS	1.251	0.640	0.261	0.638(34)	0.263	0	-
M1/M2	1.713	0.235	0.406	0.421(39)	0.337	8 (Right)	0.162 (0.034;0.289)
M1 Macrophage	10.251	0.397	0.345	1.240(66)	0.109	7 (Right)	0.421 (0.290;0.551)
M2 Macrophage	2.493	0.990	0.161	1.079(38)	0.143	0	-
Th1/Th2	0.562	0.205	0.418	0.224(43)	0.411	12 (Right)	0.149 (0.033;0.265)
Th1	5.830	0.068	0.472	0.931(43)	0.178	6 (Right)	0.353 (0.189;0.517)
Th2	7.168	0.309	0.378	0.874(55)	0.192	0	-
Th17	9.393	0.232	0.408	0.732(53)	0.233	10 (Right)	0.492 (0.332;0.651)
Neurotoxicity	7.883	0.510	0.304	1.429(60)	0.078	5 (Right)	0.327 (0.205;0.448)
CRP	12.678	1.659	0.048	2.238(36)	0.015	10 (Right)	0.776 (0.542;1.010)

M1 Macrophage: Interleukin (IL)-1β, IL-6, Tumor necrosis factor (TNF)-α, IL-12p70, IL-15, CCL2, CCL5, CXCL1, CXCL8, CXCL9, CXCL10 M2 Macrophage: IL-10, IL-4, IL-13, Vascular endothelial growth factor (VEGF), Platelet-derived growth factor (PDGF), Soluble interleukin-1 receptor antagonist (sIL-1RA)

T helper (Th)-1: IL-2, sIL-2R, interferon (IFN)-a, IFN-γ, IL-12p70, IL-16, TNF-α, TNF-β

T helper (Th)-2: IL-4, IL-5, IL-9, IL-13, IL-10, IL-6

**T helper (Th)-17:** IL-6, IL-17

**IRS:** ÎL-1α, IL-1β, IL-6, TNF-α, IL-12p70, IL-15, IL-16, IL-17, IL-18, CCL2, CCL3, CCL4, CCL5, CCL7, CCL11, CXCL1, CXCL8, CXCL9, CXCL10, IL-2, IFN-α, IFN-γ, TNF-α, TNF-β, Tumor necrosis factor related apoptosis-inducing ligand (TRAIL), Granulocyte-macrophage colony-stimulating factor (GM-CSF), Macrophage colony-stimulating factor (M-CSF), Granulocyte colony-stimulating factor (G-CSF), Stem cell growth factor-beta (SCGF).

CIRS: IL-4, IL-10, sIL-1RA, Soluble interleukin-2 receptor (sIL-2R)

Neurotoxicity: IL-1β, IL-6, TNF-α, TRAIL, IL-2, IFN-γ, IL-12p70, IL-16, IL-17, CCL2, CCL3, CCL5, CCL11, CXCL1, CXCL8, CXCL10, GM-CSF, M-CSF IRS: Immune-response system, CIRS: Compensatory immune-response system, M: Macrophage, Th: T helper, CRP: C-reactive protein,

medRxiv preprint doi: https://doi.org/10.1101/2024.02.08.24302516; this version posted February 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.




Figure 1. The PRISMA flow chart

## **IRS/CIRS**

tudy name Year		Statist	ics for each	study	Samp	le size	Std diff in means and 95% CI
		Std diff in means	Z-Value	p-Value	Patients	Controls	
Montefusco	2021	1,086	2.133	0,033	10	15	
Rico	2021	0.007	0.034	0.973	52	45	+
Loretelli	2021	0.067	0,279	0.780	39	43	<del> -</del>
Peluso	2021	0,180	0.961	0.337	73	48	<del> -</del>
Ford	2021	0.205	0.646	0.518	19	29	<del> -</del>
Sun	2021	0,114	0.257	0.797	8	16	<del> </del>
Patterson	2021	0.096	0.460	0.645	121	29	<del> -</del>
Schultheib	2022	0.402	2.019	0.043	96	36	
Williams	2022	-0,345	-0.860	0,390	12	15	
Correa	2022	-0.486	-1.576	0.115	64	13	
Meltendorf	2022	0,264	1,392	0.164	70	49	
Peluso-b	2022	0,899	4,183	0,000	52	69	
Durstenfeld	2022	-0.036	-0.178	0.858	47	55	+
Aitic	2022	0.342	0.495	0.621	15	5	<del>    -    </del>
Phetsouphanh	2022	-0.041	-0,161	0.872	31	31	
Flaskamp	2022	-0.226	-0.596	0,551	15	14	
Wiech	2022	-0,373	-0,891	0,373	15	13	<u></u> -
Ampudia	2022	1.410	2,373	0.018	12	8	
Petrella	2022	0,728	0.994	0,320	5	5	
Alfadda	2022	0.131	0.633	0.527	41	57	<del> -</del>
Queiroz	2022	0.187	1,363	0.173	135	90	<del> -</del>
Gebo	2023	0.030	0.417	0.677	292	590	+
Berezhnov	2023	-0.254	-0.927	0.354	24	32	
Neves	2023	0.140	0.951	0,342	101	95	<del> -</del>
Alejo	2023	0.008	0.033	0,973	64	25	+
Gasalla	2023	-0.272	-1,198	0.231	49	33	
Melhorn	2023	0,210	0.751	0,452	49	18	<u> -</u>
Berentschot	2023	0.022	0.099	0,921	37	42	+
Xu	2023	0.064	0,255	0,799	34	30	+
Ruiz	2023	0.344	1.152	0.249	13	89	<del> </del>
Kind	2023	0,130	0.453	0.651	27	32	
Gomes	2023	0,852	2,294	0.022	15	21	
Blitz	2023	-0.275	-0.609	0.543	10	10	<del> </del>
Park	2023	-0.654	-1.458	0.145	11	10	
Tena	2023	-0.315	-0.787	0.431	8	39	<del>_  </del>
Al-Hakeim-b	2023	0,643	3.501	0.000	61	64	
Al-Hakeim-c	2023	-0,016	-0.069	0,945	43	39	
Pooled		0,126	2,421	0,015	1770	1854	
		5,.20	_,	5,5.0		-4,00	) -2,00 0,00 2,00 4,0
						,00	, 2,00 0,00 2,00 4,0

**Figure 2.** Forest plot of immune response system (IRS)/compensatory immune response system (CIRS) in patients with Long COVID (LC) and normal controls.

#### **IRS**

Study name	Year		ics for each s	study	Samp	le size	Std diff in means and 95% Cl
		Std diff in means	Z-Value	p-Value	Patients	Controls	
Townsend	2020	-0,095	-0,538	0,590	67	61	+
Ong	2021	1,610	5,239	0,000	34	24	<del></del> +
Rico	2021	0.028	0,138	0.890	52	45	<del> </del>
Patterson	2021	0.258	1,240	0,215	121	29	<del> -</del>
Sun	2021	-0,011	-0,024	0,981	8	16	I <u>—</u> I I
Nechsler	2021	1,380	3,491	0,000	13	20	l I <u>——</u> —
Ford	2021	0,357	1,138	0,255	19	29	<u> </u>
	2021			0,235	30	30	1 T <u></u>
Boni		0,742	2,779				L==
_oretelli	2021	0,126	0,528	0,598	39	43	_ <del></del>
Aparisi	2021	0,368	1,506	0,132	41	29	<del> •</del>
Colarusso	2021	-0,040	-0,126	0,900	26	17	_ <del></del>
Peluso	2021	0,248	1,326	0,185	73	48	<del> =</del>
Vontefusco	2021	1,852	3,616	0,000	10	15	<del> </del>
an	2022	0,436	2,283	0,022	39	124	
Alfadda	2022	0,039	0,192	0,848	41	57	<del> </del>
Queiroz	2022	0.044	0,320	0.749	135	90	1 1
Patra	2022	0,272	0,406	0,685	6	4	<del>     </del>
Petrella	2022	0,681	0,919	0,358	5	5	<u> </u>
Aitic	2022	0.474	0,673	0,556	15	5	
Nilliams	2022	-0,712	-1,767	0,077	12	15	<del></del>
Ampudia	2022	2,135	3,616	0,000	12	8	<del>     </del>
<b>Viec</b> h	2022	-0,614	-1, <b>4</b> 56	0,145	15	13	<del>  </del>
Flaskamp	2022	-0,286	-0,754	0,451	15	14	<del></del>
Abellan	2022	0,402	1,342	0,180	14	58	<del>  ■</del>
_ittlefield	2022	0,715	2,191	0,028	20	20	<del> </del>
Zhao	2022	0.679	2,130	0.033	22	22	<del></del>
Kruger	2022	0,258	1,012	0,312	44	28	<del> -</del>
Taeschler	2022	0.596	2,661	0.008	51	42	_ <b></b>
Phetsouphanh	2022	-0,063	-0,248	0,804	31	31	<u>_</u>
				0,007		26	I
Gullu .	2022	-0,730	-2,679		32		I — L
Ferrando	2022	0,112	0,366	0,714	23	22	<del> </del>
Cervia	2022	0,695	3,287	0,001	67	40	<u> </u>
Durstenfeld	2022	-0,104	-0,521	0,603	47	55	+
ogarty	2022	-0,002	-0,007	0,995	50	20	<del> </del>
Peluso-b	2022	1,023	4,643	0.000	52	69	
Veltendorf	2022	0,560	2,947	0,003	70	49	
Schultheib	2022	0,573	2,878	0.004	96	36	
Vleisinger	2022	-0,153	-0,768	0.443	45	85	I ————————————————————————————————————
Aparisi-b	2022	-0.532	-1,543	0.123	10	60	I <del></del>
Saxena	2022	2.237	6,203	0.000	25	25	l ⁻l <u>↓</u> l
Correa	2022	-0.236	-0.772	0,440	64	13	IL ¬¯
							1 <del>-1</del>
3erentschot	2023	-0,010	-0,045	0.964	37	42	_ <del>_</del>
Teng	2023	-0,664	-1,668	0,095	8	39	<del>- •  </del>
Kovarik-a	2023	-1,293	-2,953	0,003	13	13	<del>  - </del>
Gomes	2023	1,074	2,838	0,005	15	21	<del></del>
3litz	2023	-0,307	-0,678	0,498	10	10	<del> -</del>
Kuchler	2023	0,000	0,001	0,999	25	16	<b>I</b> →
Kind	2023	0,413	1,443	0,149	27	32	+
Ruiz	2023	0.417	1,392	0.164	13	89	-
₹u	2023	0,106	0,418	0,676	34	30	I 📥 📗
Sommen	2023	0.108	0,415	0,576	109	115	<u>L</u>
					40		I <u>I</u>
Siekacz	2023	0,119	0,528	0,598		40	T
Melhorn	2023	0,275	0,984	0,325	49	18	<del> •</del>
Gasalla	2023	-0,262	-1,154	0,249	49	33	<del>-= </del>
∖lejo	2023	-0,042	-0,170	0,865	64	25	<del>   </del>
Schultheib-b	2023	0,597	2,716	0,007	91	28	
Nynberg	2023	0,374	2,450	0,014	101	85	
Veves	2023	-0.007	-0,050	0.960	101	95	→
Gebo	2023	0.066	0.917	0.359	292	590	I I
Berezhnoy	2023	-0,361	-1,319	0,187	24	32	l <u></u> -
	2023		3,501	0,107	61	64	
Al-Hakeim-b		0,643					
Al-Hakeim-c	2023	0,307	1,345	0,179	43	39	<del>  •</del>
Pooled		0,247	4,150	0,000	2795	2898	•

**Figure 3.** Forest plot of immune response system (IRS) in patients with Long COVID (LC) and normal controls.

### M1 Macrophage

tudy name	Year		cs for each	study	Samp	le size	Std diff in means and 95% CI
		Std diff in means	Z-Value	p-Value	Patients	Controls	
ownsend	2020	-0,095	-0,538	0,590	67	61	🔫
parisi	2021	0,368	1,506	0,132	41	29	<del> =</del>
olarusso	2021	-0,599	-1,865	0,062	26	17	<del>  •  </del>
ord	2021	0,510	1,792	0,073	24	29	<del> -</del>
ord-2	2021	0,756	2,122	0,034	12	29	
retelli	2021	0,107	0,455	0,649	39	43	<del> -</del>
ontefusco	2021	2,054	3,785	0,000	10	15	
ing	2021	1,639	5,308 1,343	0,000	34 <b>12</b> 1	24 29	<u></u>
atterson atterson-1	2021 2021	0,278 0,173	0,832	0,179 0,405	121	29 29	
auerson-i eluso	2021	0,173	1,250	0,405	73	48	1 1 1
ico	2021	-0,012	-0,061	0,951	52	45	
oni	2021	0,742	2,779	0,005	30	30	│ │ <u></u>
un.	2021	0.277	0.618	0,537	8	16	<del> </del>
/echsler	2021	1,380	3,491	0,000	13	20	
pellan	2022	0,402	1,342	0,180	14	58	│
tic	2022	0,868	1,366	0,172	10	5	<del>                                   </del>
tic-1	2022	1,186	1,774	0,076	19	5	<del>  •  </del>
fadda	2022	0,009	0,043	0,966	41	57	+
npudia	2022	1,8 <b>1</b> 0	3,172	0,002	12	8	
oarisi-b	2022	-0,532	-1,543	0,123	10	60	
ervia	2022	0,695	3,287	0,001	67	40	——
orrea	2022	-0,236	-0,772	0,440	64	13	<del>  </del>
urstenfeld	2022	-0,003	-0,017	0,987	47	55	<del>                                   </del>
an arrando	2022	1,282	6,513	0,000	39	124	
errando askamp	2022 2022	0,112 -0,137	0,366 -0.365	0,714 0,715	23 15	22 14	
	2022	-0,137	-0,363	0,715	50	20	
garty uger	2022	0,258	1,012	0,312	44	28	
tlefield	2022	0.715	2.191	0.028	20	20	<u>-</u>
eisinger	2022	0.251	1.366	0,172	53	88	<del> _</del>
eltendorf-1	2022	0.696	3.633	0.000	70	49	<b> </b>
itra-1	2022	0,471	0,698	0,485	6	4	
eluso-b	2022	1,891	8,176	0,000	52	69	│
trella	2022	0,420	0,579	0,562	5	5	<del>  - -</del>
etsouphanh	2022	-0,051	-0,201	0,841	31	31	<del> </del>
Jeiroz	2022	-0,165	-1,210	0,226	135	90	<del>  •</del> †
xena	2022	2,237	6,203	0,000	25	25	∣
hultheib	2022	0,583	2,925	0,003	96	36	<del></del>
eschler eschler-1	2022 2022	0,552 0.727	2,500 3,120	0,012 0,002	53 45	42 42	
escnier-1 ech	2022	-0,906	-2,135	0,002	45 15	13	<u> </u>
lliams	2022	-0,900 -0,694	-2,135 -1,720	0,033	12	15	
ao	2022	1,135	3,484	0,000	22	22	
aio oio	2023	-0,096	-0.398	0,600	64	25	
rentschot	2023	-0,005	-0,021	0,983	37	42	🚣
rezhnoy	2023	-0,371	-1,358	0,175	24	32	
z	2023	-0,705	-1,529	0,126	10	10	<del> </del>
tz-1	2023	-0,050	-0,111	0,912	10	10	
salla	2023	-0.227	-1,000	0,318	49	33	<del>  = </del>
bo	2023	0,159	2,214	0,027	292	590	<b> -  -</b>
mes	2023	0,775	2,203	0,028	15	21	
mes-1	2023	0,098	0,291	0,771	15	21	<del> </del>
nd	2023	0,451	1,526	0,127	27	32	<del> •</del>
varik-a	2023	-0,747	-1,842	0,066	13	13	<del></del>
chler	2023	0,000	0,001	0,999	25	16	<del>   </del>
lhorn	2023	0,654	2,315	0,021	49	18	
ves	2023	-0,351	-2,390	0,017	101	95 89	<del>"</del>
iz nultheib-b	2023 2023	0,384 0.635	1,286 2.885	0,198 0,004	13 91	89 28	T <u></u>
nuitneib-b kacz	2023	0,635	1.838	0,004	40	28 40	
mmen	2023	0,415	0.818	0,000	109	115	
ng	2023	-0,592	-1,498	0,413	8	39	
ynberg	2023	0,523	3,395	0,001	101	85	
ynoeig I	2023	0,009	0,034	0,973	34	30	
, J-1	2023	0,073	0.292	0,770	34	30	<u> </u>
-Hakeim-b	2023	0,769	4.146	0,000	61	64	│
l-Hakeim-c	2023	0,446	1.943	0,052	43	39	<u>  -                               </u>
		0,327	5,015	0,000	3030	3042	ı ı l - l

Figure 4. Forest plot of Macrophage M1 in patients with Long COVID (LC) and normal controls.

# T-helper 1

Study name	Year	Statisti	cs for each	study	Samp	le size	Std diff in means and 95% CI
		Std diff in means	Z-Value	p-Value	Patients	Controls	
Ong	2021	1,698	5,444	0,000	34	24	
Rico	2021	-0,020	-0,099	0,921	52	45	+
Patterson	2021	0,279	1,342	0,180	121	29	
Sun	2021	0.229	0,508	0,611	8	16	<del> </del>
Montefusco	2021	2.012	3,948	0,000	10	15	
ord	2021	0,338	1,078	0,281	19	29	<del> </del>
_oretelli	2021	0,288	1,222	0,222	39	43	<del> -</del>
Peluso	2021	0,273	1,459	0,145	73	48	
Alfadda	2022	-0,015	-0.072	0,943	41	57	<del> </del>
Queiroz	2022	0,107	0,781	0,435	135	90	
Patra	2022	0,221	0,342	0,732	6	4	<del>   -</del>
Petrella	2022	0,619	0,849	0,396	5	5	
Aitic	2022	-1,638	-2,143	0,032	14	5	<u>                                    </u>
Nilliams	2022	-0,355	-0,906	0,365	12	15	- <u>-                                </u>
Ampudia	2022	2,028	3,573	0,000	12	8	
Niech	2022	-0.708	-1,773	0,000	15	13	
Flaskamp	2022	0,327	0,870	0,076	15	14	
hao	2022	0,327	1,364	0,364	22	22	
	2022	2,237		0,173	25	25	
Saxena		, -	6,203	-,			<del>       </del>
Taeschler	2022	0,589	2,620	0,009	51	42	
Phetsouphanh		-0,248	-0,968	0,333	31	31	<del></del>
errando	2022	-0,448	-1,563	0,118	26	24	
Meisinger	2022	-0,355	-1,721	0,085	41	83	<del></del>
Cervia	2022	0,697	3,271	0,001	67	40	<del></del>
Durstenfeld	2022	-0,232	-1,163	0,245	47	55	
Peluso-b	2022	0,676	2,948	0,003	52	69	<del> </del>
Correa	2022	-0,042	-0,138	0,890	64	13	
vleltendorf	2022	0,697	3,637	0,000	70	49	
Schultheib	2022	0,751	3,731	0,000	96	36	
eng	2023	-1,121	-2,758	0,006	8	39	
Gomes	2023	1,426	3,499	0,000	15	21	<del> </del>
Blitz	2023	-0,581	-1,273	0,203	10	10	
Kind	2023	-0,290	-1,073	0,283	27	32	
Ruiz	2023	0,545	1,812	0,070	13	89	<del>  -</del>
Berezhnoy	2023	-0,551	-1,997	0,046	24	32	<del> </del> -
(u	2023	0,283	1,123	0,262	34	30	<del> =</del>
Berentschot	2023	-0,154	-0,683	0,495	37	42	<del>   </del>
Sommen	2023	0,156	0,887	0,375	109	115	<del> -</del>
Siekacz	2023	-0,064	-0,285	0,776	40	40	
Melhorn	2023	0.464	1,659	0,097	49	18	+
Gasalla	2023	-0,521	-2,276	0,023	49	33	
Alejo	2023	-0,128	-0,532	0,595	64	25	<u></u>
Nynberg	2023	0,878	5,517	0,000	101	85	-
Neves	2023	0,058	0,397	0,691	101	95	+
Gebo	2023	0,032	0,450	0,653	292	590	[
Pooled	2020	0,230	2,869	0,004	2175	2245	
ooleu		0,230	۷,008	0,004	2113	2243	-4,00 -2,00 0,00 2,00 4,0

Figure 5. Forest plot of T helper (Th 1) in patients with Long COVID (LC) and normal controls.



tudy name Year			cs for each	study	Samp	le size	Std diff in means and 95% CI
		Std diff in means	Z-Value	p-Value	Patients	Controls	
ownsend	2020	-0,095	-0,538	0,590	67	61	🛶
ng	2021	1,581	5,170	0,000	34	24	
Rico	2021	0,016	0,079	0,937	52	45	+
atterson	2021	0.502	2.406	0.016	121	29	<del></del>
Vechsler	2021	1,558	3.851	0,000	13	20	│
ord	2021	0,248	0.785	0,433	19	29	<del> </del>
ioni	2021	0.742	2,779	0.005	30	30	<u></u>
Colarusso	2021	-0,599	-1.865	0.062	26	17	<u> </u>
eluso	2021	0,418	2,224	0.026	73	48	<u>-</u>
oretelli	2021	0,159	0,718	0.473	39	43	<u> </u>
Montefusco				0.290	10	15	<u>                                   </u>
	2021	0,453	1,058		10 <b>4</b> 1		
parisi	2021	0,368	1,506	0,132		29	<del>  -</del> _
an	2022	1,282	6,513	0,000	39	124	<del> </del>
Ifadda	2022	0,662	3,151	0,002	41	57	<del></del>
Queiroz	2022	-0,051	-0.370	0,711	135	90	+
ijtic	2022	3,102	4,136	0,000	18	4	
Villiams	2022	-0,918	-2,255	0,024	12	15	<del>  •</del>
mpudia	2022	2,887	4,473	0,000	12	8	
Viech	2022	-0,978	-2,372	0,018	15	13	
laskamp	2022	-0,245	-0.653	0,514	15	14	│ <del>│ <u>─</u>■</del>
ittlefield	2022	0,715	2,191	0.028	20	20	
hao	2022	0,878	2,777	0,005	22	22	
ruger	2022	0,258	1,012	0,312	44	28	<u> </u> -
chultheib	2022	0,501	2,532	0,312	96	36	
aeschler	2022	0,603	2,532	0.007	90 51	42	
hetsouphanh	2022	0,176	0,693	0,488	31	31	
Bullu .	2022	-0,730	-2,679	0,007	32	26	
errando	2022	0,673	2,069	0,039	20	20	<del>  -</del>
urstenfeld	2022	0,152	0,766	0,443	47	55	<del> =</del> -
etrella	2022	-0,653	-0,920	0,358	5	5	
ogarty	2022	-0,002	-0,007	0,995	50	20	<del>   </del>
eluso-b	2022	2,413	10,035	0,000	52	69	
leltendorf	2022	0,469	2,480	0,013	70	49	
leisinger	2022	0,251	1.366	0,172	53	88	<del> -</del>
parisi-b	2022	-0.532	-1.543	0.123	10	60	<del>  _</del>
orrea	2022	-0,429	-1. <b>401</b>	0.161	64	13	<del>                                   </del>
bellan	2022	0.402	1.342	0.180	14	58	
ervia	2022	0,693	3,303	0.001	67	40	<u>-</u> -
ervia erentschot	2022	0,093	1,292	0,001	37	40 42	
							TT
Somes	2023	0,445	1,289	0,198	15	21	<del>  •  </del>
litz	2023	-0,190	-0,422	0,673	10	10	<del>- •</del>
leves	2023	-0,105	-0,705	0,481	101	95	
uchler	2023	-0,284	-0,884	0,377	25	16	<del>  • </del>
and	2023	0,686	2,551	0,011	27	32	<del></del>
ebo	2023	0,158	2,200	0,028	292	590	-  -
Ruiz	2023	0,267	0,899	0,369	13	89	<del> =</del>
(u	2023	-0,250	-0.988	0,323	34	30	<del>-= </del>
iekacz	2023	0,487	2 146	0.032	40	40	
lelhorn	2023	0,524	1.867	0.062	49	18	<del>  _</del>
Sasalla	2023	-0,215	-0.953	0.341	49	33	<del></del>
dejo	2023	-0,435	-1,801	0,072	64	25	<u></u> _
eng	2023	-0,433	-0.532	0,595	8	39	<u></u>
eng ichultheib-b	2023	0,472		0.031	91	28	<u> </u>
			2,162				<u>                                   </u>
erezhnoy	2023	-0,391	-1,434	0,152	24	32	<del> </del>
Vynberg	2023	0,847	5,462	0,000	101	85	
ooled		0,316	4,067	0,000	2539	2622	
						-4	00 -2,00 0,00 2,00

Figure 6. Forest plot of T helper (Th) 17 in patients with Long COVID (LC) and normal controls.

#### **Neurotoxicity**




Figure 7. Forest plot of neurotoxicity in patients with Long COVID (LC) and normal controls.